

**Curriculum Vitae for: Claudio Anasetti, M.D.**  
**Date: January 23, 2014**

---

**Current Position:** Professor  
Department of Oncologic Sciences, MDC 44  
Department of Pathology & Cell Biology  
College of Medicine  
University of South Florida

Senior Member and Chair, Department of Blood and Marrow Transplantation  
Moffitt Cancer Center and Research Institute

12902 Magnolia Drive  
Tampa, Florida 33612  
(813) 745-2557 - Phone  
(813) 745-8468 - Fax  
Email address: Claudio.Anasetti@Moffitt.org

**Education:**

1969 – 1974 ‘Cornelius Tacitus’ High School in Terni, Italy, graduated cum laude  
1974 – 1980 School of Medicine, University of Perugia, Italy, M.D. cum laude

**Postgraduate Training and Fellowship Appointments:**

1980 – 1982 Resident in Internal Medicine, University of Perugia, Italy  
1982 – 1983 Fellow in Immunology, Children’s Memorial Hospital, Oklahoma City, and  
Associate Research Scientist, Oklahoma Medical Research Foundation, Oklahoma City  
1983 – 1985 Fellow in Oncology, Department of Medicine, University of Washington and Fred  
Hutchinson Cancer Research Center, Seattle, Washington

**Academic Appointments and Employment:**

1985 – 1987 Associate in Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington  
1987 – 1992 Assistant Member, Fred Hutchinson Cancer Research Center, Seattle, Washington  
1992 – 1998 Associate Member, Fred Hutchinson Cancer Research Center, Seattle, Washington  
1994 – 1999 Associate Professor of Medicine, University of Washington, Seattle, Washington  
1998 – 2004 Member, Fred Hutchinson Cancer Research Center, Seattle, Washington  
1999 – 2004 Professor of Medicine, University of Washington, Seattle, Washington  
2004 – Member-in-Residence, Moffitt Cancer Center and Research Institute, Tampa, Florida  
2004 – Professor of Oncology, University of South Florida, Tampa, Florida  
2006 – Professor of Internal Medicine, Joint Appointment, University of South Florida, Tampa, Florida  
2008 – Senior Member, Moffitt Cancer Center and Research Institute, Tampa, Florida  
2011 – Professor, Department of Pathology & Cell Biology, University of South Florida, Tampa, Florida

**Administrative Appointments:**

1990 – 2004 Medical Director, Unrelated Donor Marrow Transplant Program, Fred Hutchinson Cancer Res. Center  
2004 – 2008 Chief, Division of Blood and Marrow Transplantation, Moffitt Cancer Center & Research Institute  
2008 – Chair, Department of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute

**Clinical Teaching:**

2004 – 2009 BMT Fellowship Training Director  
2010 – BMT Fellowship Training Director

**Licenses:**

1985 – 2004 Washington State License #252-09-0022412  
2004 – Florida Medical License #ME-92747

**Board Certifications:**

1980 Italian Board Examination for M.D.  
1981 Educational Commission for Foreign Medical Graduates (ECFMG)  
1982 Visa Qualifying Examination (VQE)  
1984 Federal Licensure Examination (FLEX)  
1985 Italian Board of Internal Medicine  
1995 American Board of Internal Medicine  
2005 Recertification of American Board of Internal Medicine  
2006 American Board of Medical Oncology

**Clinical Activities:**

1985 – 2004 Attending physician with privileges in Internal Medicine & Oncology, Swedish Hospital Medical Center, Seattle, WA  
2001 – 2004 Attending physician with privileges in Internal Medicine & Oncology, University of Washington Medical Center, and Seattle Cancer Care Alliance, Seattle, WA.  
2004 – Attending physician with privileges in Internal Medicine, Moffitt Cancer Center and Research Institute, Tampa, Florida  
2006 – Attending physician with privileges in Oncology and Blood & Marrow Transplant, Moffitt Cancer Center

**Honors:**

Hawkins Family Foundation Chair in Blood and Marrow Transplantation

**Editorial Boards:**

1997 – 2002 Blood  
1997 – 2002 Hematologica  
2002 – Biology of Blood and Marrow Transplantation

**Journal Reviewer:**

New England Journal of Medicine  
Nature Medicine  
Blood  
Biology of Blood and Marrow Transplantation  
The Journal of Experimental Medicine  
Immunity  
Journal of Immunology  
Journal of Clinical Investigation

**Professional Association Memberships**

1992 – Member, American Society of Hematology  
1994 – Member, American Society of Blood and Marrow Transplantation  
2007 – 2008 Vice-President American Society of Blood and Marrow Transplantation  
2008 – 2009 President-elect American Society of Blood and Marrow Transplantation  
2009 – 2010 President American Society of Blood and Marrow Transplantation

**National Committees:**

1991 – 1992 Member, National Marrow Donor Program (NMDP) Research and Publication Ad Hoc Committee  
1991 – 1996 Member, Standards Committee of the NMDP, Minneapolis, MN  
1992 – Member, National Children Cancer Society Medical Advisory Board  
2000 Ad Hoc Reviewer, NIH, Review Committee of Immunology PO1s  
2000 – 2004 Member, Research and Publication Committee of the NMDP  
2001 – 2007 Member, American Society of Hematology, Lymphocyte Biology Committee  
2001 – 2003 Ad Hoc Reviewer, NIH, ET-2 study section  
2001 – 2003 Member, Board of Directors, NMDP

2001 – 2003 Member, Histocompatibility Committee of the NMDP  
2001 – 2002 Council President, NMDP  
2001 – Chair, Clinical Trial Network 0201 trial: PBSC versus Marrow Transplants from Unrelated Donors  
2002 Ad Hoc Reviewer, NIH, ET-1 study section  
2003 – 2004 Ad Hoc Reviewer, NIH, CII study section  
2004 – 2005 Chair, Histocompatibility Committee of the NMDP  
2005 – 2007 Chair, GVHD Committee, Center for Blood and Marrow Transplant Research (CIBMTR)  
2005 Member, National Institutes of Health, Cancer Immunopathology and Immunotherapy Study Section, Center for Scientific Review  
2005 Special Emphasis Panel Reviewer, NIH, Approaches in Cancer Therapy Study Section ZRG1 ONC-U01  
2005 – 2011 Member, Board of Directors, American Society of Blood and Marrow Transplantation  
2005 – 2007 Chair, Scientific Affairs Counsel American Society of Blood and Marrow Transplantation  
2005 – 2006 Member, American Society of Clinical Oncology (ASCO) Scientific Program Committee  
2005 – 2006 Scientific Chair, ASBMT/CIBMT 2006 meeting  
2007 NIH, TTT study section, ad hoc reviewer  
2007 Ad Hoc Reviewer, NIH, PO1 study section on Blood Disorders  
2007 – 2008 ASH Scholar Awards Study Section  
2007 – 2009 Chair, American Society of Hematology, Lymphocyte Biology Committee  
2010 – 2014 Charter Member, NIH, Clinical Oncology Study Section, Center for Scientific Review  
2010 – 2011 Chair, Strategic Capacity Initiative Physician Workforce Group, and Member, Strategic Capacity Initiative Steering Committee, National Marrow Donor Program (NMDP)  
2011 – Member, Steering committee, BMT Clinical Trial Network

**National Forums, Expert Panels and Consensus Conferences:**

1990 Ad Hoc NMDP Panel on “Bylaws and Operating Policies”, Minneapolis, MN  
1991 Member, Ad hoc Panel on Recomputerization of the NMDP Registry  
1992 Ad Hoc FDA Panel on “Preclinical Safety Testing of Monoclonal Antibodies”, Bethesda, MD  
1992 Ad Hoc NMDP Panel on “Data Collection and Quality Control”, Washington, D.C.  
1993 Ad Hoc NMDP Panel on “Policy for Donor DR typing”, Minneapolis, MN  
1996 “Consensus Conference on Unrelated Donor Marrow Transplantation”, Edinburgh, Scotland  
1997 “National Forum on Marrow Donation and Transplantation”, Arlington, VA  
1999 Cord Blood NIH Ad Hoc Panel, Bethesda, MD. Attendee  
2000 National Forum on Hematopoietic Stem Cell Transplantation from Unrelated Donors, Ottawa, Canada. “The Future of Unrelated Stem Cell Transplantation: An Overview of Novel Transplant Technology and Transplant Options.”  
2002 Member, IBMTR/ABMTR/NMDP Collaborative Work Group Panel (CIBMTR Founding Meeting); Minneapolis, MN.  
2006 Member, Blood and Marrow Transplant-Clinical Trials Network Steering Committee, State of the Science Cabinet  
2007 – 2013 Member, Advisory Council on Blood Stem Cell Transplantation of the US Government Health Resources and Services Administration  
2010 – Chair, State of Florida Blood Marrow Transplant Advisory Panel

**Fred Hutchinson Cancer Research Center Institutional Committees:**

1986 – 1990 Member, Institutional Review Board, FHCRC  
1993 – 1995 Member, Quality Improvement and Utilization Committee  
1997 – 1999 Member, Committee on Clinical Staffing Models  
1997 – 1999 Member, Ethics Committee  
1998 – 2004 Member, Medical Executive Committee  
1999 – 2000 Member, Physician’s Practice Model  
2000 – 2000 Member, Ad Hoc Committee for Clinical Trial Management  
2000 – 2004 Member, Scientific Review Committee

### **H. Lee Moffitt Cancer Center & Research Institutional Committees:**

2004 – 2005 Member, Scientific Review Committee  
2004 – 2006 Member, Clinical Investigation Steering Committee  
2004 – Member, Medical Executive Committee  
2004 – Member, DIO Division Chief /MMG Executive Committee  
2004 – Member, BMT Quality Improvement Committee  
2004 – Member, BMT/USF Managed Care Committee  
2005 – 2006 Chair, Scientific Review Committee  
2006 – Member, Scientific Leadership Council  
2006 – 2009 Member, Scientific Review Committee

### **Patents**

1993 U.S. #5,273,738 Radiation Delivery to Lymphoid and Marrow Tissues  
1994 U.S. #5,834,597 Mutated Non-activating IgG2 Domains and Anti CD3 Antibodies Incorporating the Same

### **Research Support**

#### **Current**

**1R01HL114994 (P.I.: Anasetti, C.)** 7/01/2013 – 06/30/2018 1.2  
NIH/NHLBI Annual Direct Costs \$277,904  
Adoptive transfer of donor Tregs specific against host alloantigens for prevention of acute GVHD  
The goal of this grant is to investigate adoptive transfer of donor Tregs specific against host alloantigens for prevention of human GVHD.

**1U10 HL108987-02 (P.I.: Anasetti, C.)** 8/08/20011 - 6/30/2017 1.2  
NCI/NHLBI Annual Direct Costs \$99,000  
Blood & Marrow Transplant Clinical Research Center  
Blood & Marrow Transplant Clinical Research Network will promote efficient comparison of novel treatment methods and management strategies of potential benefit for children and adults undergoing blood or marrow transplantation.

**1R01CA160684-02 (P.I.: Syrjala, K.)** 1/01/2012 – 5/31/2016  
Subcontract Annual Direct Costs \$40,000  
Anasetti, C; Co-Investigator. .3  
Fred Hutchinson Cancer Research Center is the coordinating center for a multi-center research study. The goal of this project is to investigate the promotion of health in long-term survivors after blood and marrow transplantation (BMT) including cancer-related distress and health care needs.

#### **Completed:**

Title: American Cancer Society Development Award  
Dates: 7/1/1989 – 6/30/1992  
Total Award: \$ 150,000

Account#: P01 AI 29518 (P.I.: Hansen, J.)  
Source: NIH/NIAID  
Title: Immunogenetics of Marrow Allografting

Title: Project: 5 (Project Leader: Anasetti, C.)  
Cellular Regulations of Alloimmune Responses  
Dates: 6/1/1989 – 5/30/1992  
Total Award Project 5: \$210,000

Account#: P01 CA 36444 (P.I.: Storb, R.)  
 Source: NIH/NIAID  
 Title: Marrow Transplantation for Severe Aplastic Anemia  
  
 Project: 5 (Project Leader: Anasetti, C.)  
 Title: Unrelated and HLA mismatched Related Donor Transplants  
 Dates: 5/1/1991 – 4/30/1996  
 Total Award Project 5: \$275,000

Account#: P01 CA 18221 (P.I.: Storb, R.)  
 Source: NIH/NIAID  
 Title: Immunology of Marrow Transplantation  
  
 Project: 8 (Project Leader: Anasetti, C.)  
 Title: Induction of Peripheral Tolerance  
 Dates: 5/1/1992 – 4/30/1997  
 Total Award Project 8: \$594,000

Account#: P01 AI 33484 (P.I.: Hansen, J.)  
 Source: NIH/NIAID  
 Title: Immunogenetics of Marrow Allografting  
  
 Project: 4 (Project Leader: Anasetti, C.)  
 Title: T cell tolerance to allogeneic stem cells  
 Dates: 9/30/1992 – 9/30/2000  
 Total Award Project 4: \$880,000

Project: 2 (Project Leader: Anasetti, C.)  
 Title: Immune Deviation of Tolerance Induced by Human Lymphoid Dendritic Cells  
 Dates: 10/1/2000 – 3/15/2004  
 Total Award Project 2: \$456,303

Account#: P01 CA 18029 (P.I.: Appelbaum, F.)  
 Source: NIH/NCI  
 Title: Adult Leukemia Research Center  
  
 Project: 4 (Project Leader: Anasetti, C.)  
 Title: Tolerance Induction by Therapeutic Monoclonal Antibodies  
 Dates: 12/1/1996 – 11/30/2001  
 Total Award Project 4: \$1,324,000

Account#: R01 AI 40680 (P.I.: Anasetti, C.)  
 Source: NIH/NIAID  
 Title: Antigen Specific T-Cell Tolerance by Anti-CD3 Antibodies  
 Dates: 5/1/1998 – 4/30/2001  
 Total Award: \$ 520,842

Account#: R21 AI 40680 (P.I.: Anasetti, C.)  
 Source: NIH/NIAID  
 Title: Antigen Specific T-Cell Tolerance by Anti-CD3 Antibodies  
 Dates: 5/1/2001 – 4/30/2002  
 Total Award: \$ 225,000

Project: 3 (Project Leader: Anasetti, C.)  
 Title: Induction of Immunological Tolerance after Hematopoietic Stem Cell Grafts

Dates: 12/1/2001 – 3/15/2004  
Total Award Project 3: \$1,105,195

Account #: R01 AI 51593-05 (P.I.: Anasetti, C.)  
Source: NIH/NIAID  
Title: Antigen Specific T-Cell Tolerance by Anti-CD3 Antibodies  
Dates: 5/1/2002 – 4/30/2007  
Total Award Amount \$1,125,000

Account # P01 CA111412-01 (P.I.: Miller, J)  
Source: NIH/NCI  
Title: NK Cells, Their Receptors and unrelated Donor Transplant  
Dates: 11/1/2004 – 10/31/2009

Sub Project: 3 (Project Leader D. Weisdorf)  
Title: Clinical Transplantation Exploiting NK Activity  
Role: Protocol Co-Investigator  
Annual Direct Costs \$198,898

Account: 1R21AI082498-02 (PI: Anasetti, C.)  
Source: NIH/NIAID  
Title: Peripheral T Cell Tolerance by Targeting AKT  
Dates: 5/15/2009-4/30/2011  
Annual Direct Costs \$150,000

**Account: RO1CA132197-10 (PI: Anasetti, C.)**  
Source: NHI/NCI  
Title: Antigen Specific T-Cell Tolerance by Anti-CD3 Antibodies  
Dates: 5/01/2004-7/31/2013  
Annual Direct Costs: \$218,000

### **Peer-Reviewed Original Publications**

1. Liberati, A.M., Di Costanzo, F., **Anasetti, C.**, Buzzi, F., Falchi, R., Grignani, F.: Humoral nonparathyroid hypercalcemia without evidence of bone involvement. *Tumori*. 69: 223-226, 1983.
2. Landreth, K.S., Engelhard, D., **Anasetti, C.**, Kapoor, N., Kincade, P.W., Good, R.A.: Pre-B cells in agammaglobulinemia: Evidence for disease heterogeneity among affected boys. *J. Clin. Immunol.* 5: 84-89, 1985.
3. **Anasetti, C.**, Doney, K.C., Storb, R., Meyers, J.D., Farewell, V.T., Buckner, C.D., Appelbaum, F.R., Sullivan, K.M., Clift, R.A., Deeg, H.J., Fefer, A., Martin, P.J., Singer, J.W., Sanders, J.E., Stewart, P.S., Witherspoon, R.P., Thomas, E.D.: Marrow transplantation for severe aplastic anemia: Long term outcome in fifty "untransfused" patients. *Ann. Intern. Med.* 104: 461-466, 1986.
4. **Anasetti, C.**, Martin, P.J., Morishita, Y., Badger, C.C., Bernstein, I.D., Hansen, J.A.: Human large granular lymphocytes express high affinity receptors for murine monoclonal antibodies of the IgG3 subclass. *J. Immunol* 138: 2979-2981, 1987.
5. Beatty, P.G., Di Bartolomeo, P., Storb, R., Clift, R.A., Buckner, C.D., Sullivan, K.M., Doney, K., Appelbaum, F.R., **Anasetti, C.**, Witherspoon, R., Sanders, J., Stewart, P., Martin, P.J., Ciancarelli, M., Hansen, J.A., Thomas, E.D.: Treatment of aplastic anemia with marrow grafts from related donors other than HLA genotypically-matched siblings. *Clin. Transplant* 1: 117-124, 1987.
6. **Anasetti, C.**, Martin, P.J., June, C.H., Hellstrom, K.E., Ledbetter, J.A., Rabinovitch, P.S., Morishita, Y., Hellstrom, I., Hansen, J.A.: Induction of calcium flux and enhancement of cytolytic activity in NK cells by crosslinking of the sheep erythrocyte binding protein (CD2) and the FC-receptor (CD16). *J. Immunol* 139: 1772-1779, 1988.
7. Martin, P.J., Hansen, J.A., **Anasetti, C.**, Zutter, M., Durnam, D., Storb, R., Thomas, E.D.: Treatment of

- acute graft-versus-host disease with anti-CD3 monoclonal antibodies. *Am. J. Kidney Dis.* 11: 149-152, 1988.
8. Sullivan, K.M., Witherspoon, R.P., Storb, R., Deeg, H.J., Dahlberg, S., Sanders, J.E., Appelbaum, F.R., Doney, K.C., Weiden, P., **Anasetti, C.**, Loughran, T.P., Hill, R., Shields, A., Yee, G., Shulman, H., Nims, J., Strom, S., Thomas, E.D.: Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease. *Blood* 72: 555-561, 1988.
  9. Sullivan, K.M., Witherspoon, R.P., Storb, R., Weiden, P., Flournoy, N., Dahlberg, S., Deeg, H.J., Sanders, J.E., Doney, K.C., Appelbaum, F.R., McGuffin, R., McDonald, G.B., Meyers, J., Schubert, M.M., Gauvreau, J., Shulman, H.M., Sale, G.E., **Anasetti, C.**, Loughran, T.P., Strom, S., Nims, J., Thomas, E.D.: Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-versus-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. *Blood* 72: 546-554, 1988.
  10. Sullivan, K.M., Storb, R., Witherspoon, R.P., Weiden, P.L., **Anasetti, C.**, Appelbaum, F.R., Beatty, P., Buckner, C.D., Deeg, H.J., Doney, K., Fisher, L., Loughran, T.P., Martin, P., Meyers, J., McDonald, G.B., Sanders, J., Shulman, H., Stewart, P., Thomas, E.D.: Deletion of immunosuppressive prophylaxis after marrow transplantation increases hyperacute graft-versus-host disease but does not influence chronic graft-versus-host disease or relapse in patients with advanced leukemia. *Clin. Transplant.* 3: 5-11, 1989.
  11. **Anasetti, C.**, Amos, D., Beatty, P.G., Appelbaum, F.R., Bensinger, W., Buckner, C.D., Clift, R., Doney, K., Martin, P.J., Mickelson, E., Nisperos, B., O'Quigley, J., Ramberg, R., Sanders, J.E., Stewart, P., Storb, R., Sullivan, K.M., Witherspoon, R.P., Thomas, E.D., Hansen, J.A.: Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. *N. Engl. J. Med* 320: 197-204, 1989.
  12. **Anasetti, C.**, Rybka, W., Sullivan, K.M., Banaji, M., Slichter, S.J.: Graft-v-host disease is associated with autoimmune-like thrombocytopenia. *Blood* 73: 1054-1058, 1989.
  13. Sullivan, K.M., Weiden, P.L., Storb, R., Witherspoon, R.P., Fefer, A., Fisher, L., Buckner, C.D., **Anasetti, C.**, Appelbaum, F.R., Badger, C., Beatty, P., Bensinger, W., Berenson, R., Bigelow, C., Cheever, M.A., Clift, R., Deeg, H.J., Doney, K., Greenberg, P., Hansen, J.A., Hill, R., Loughran, T., Martin, P., Neiman, P., Petersen, F.B., Sanders, J., Singer, J., Stewart, P., Thomas, E.D.: Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. *Blood* 73: 1720-1728, 1989.
  14. Storb, R., Deeg, H.J., Pepe, M., Appelbaum, F.R., **Anasetti, C.**, Beatty, P., Bensinger, W., Berenson, R., Buckner, C.D., Clift, R., Doney, K., Longton, G., Hansen, J., Hill, R., Loughran, T., Jr., Martin, P., Singer, J., Sanders, J., Stewart, P., Sullivan, K., Witherspoon, R., Thomas, E.D.: Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. *Blood* 73: 1729-1734, 1989.
  15. Storb, R., Deeg, H.J., Pepe, M., Doney, K., Appelbaum, F., Beatty, P., Bensinger, W., Buckner, C.D., Clift, R., Hansen, J., Hill, R., Longton, G., **Anasetti, C.**, Martin, P., Loughran, T.P., Sanders, J., Singer, J., Stewart, P., Sullivan, K.M., Witherspoon, R., Thomas, E.D.: Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: Long-term follow-up of a controlled trial. *Br. J. Haematol* 72: 567-572, 1989.
  16. Appelbaum, F.R., Barrall, J., Storb, R., Fisher, L.D., Schoch, G., Ramberg, R.E., Shulman, H., **Anasetti, C.**, Bearman, S.I., Beatty, P., Bensinger, W.I., Buckner, C.D., Clift, R.A., Hansen, J.A., Martin, P., Petersen, F.B., Sanders, J.E., Singer, J., Stewart, P., Sullivan, K.M., Witherspoon, R.P., Thomas, E.D.: Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. *Ann. Intern. Med* 112: 590-597, 1990.
  17. **Anasetti, C.**, Martin, P.J., Hansen, J.A., Appelbaum, F.R., Beatty, P.G., Doney, K., Harkonen, S., Jackson, A., Reichert, T., Stewart, P., Storb, R., Sullivan, K.M., Thomas, E.D., Warner, N., Witherspoon, R.P.: A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. *Transplantation* 50: 49-54, 1990.
  18. Clift, R.A., Buckner, C.D., Appelbaum, F.R., Bearman, S.I., Petersen, F.B., Fisher, L.D., **Anasetti, C.**, Beatty, P., Bensinger, W.I., Doney, K., Hill, R., McDonald, G., Martin, P., Sanders, J., Singer, J., Stewart, P., Sullivan, K.M., Witherspoon, R., Storb, R., Hansen, J., Thomas, E.D.: Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two

- irradiation regimens. *Blood* 76: 1867-1871, 1990.
19. Martin, P.J., Schoch, G., Fisher, L., Byers, V., **Anasetti, C.**, Appelbaum, F.R., Beatty, P.G., Doney, K., McDonald, G.B., Sanders, J.E., Sullivan, K.M., Storb, R., Thomas, E.D., Witherspoon, R.P., Lomen, P., Hannigan, J., Hansen, J.A.: A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. *Blood* 76: 1464-1472, 1990.
  20. Tan, P., **Anasetti, C.**, Martin, P.J., Hansen, J.A.: Alloantigen-specific T suppressor-inducer and T suppressor-effector cells can be activated despite blocking the IL-2 receptor. *J. Immunol.* 145: 485-488, 1990. PMID:PMC2188750
  21. **Anasetti, C.**, Tan, P., Hansen, J.A., Martin, P.J.: Induction of specific nonresponsiveness in unprimed human T cell by anti-CD3 antibody and alloantigen. *J. Exp. Med* 172: 1691-1700, 1990.
  22. **Anasetti, C.**, Beatty, P.G., Storb, R., Martin, P.J., Mori, M., Sanders, J.E., Thomas, E.D., Hansen, J.A.: Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. *Hum. Immunol* 29: 79-91, 1990.
  23. Schmid, I., **Anasetti, C.**, Petersen, F.B., Storb, R.: Marrow transplantation for severe aplastic anemia associated with exposure to quinacrine. *Blut* 61: 1-3, 1990.
  24. Storb, R., Pepe, M., **Anasetti, C.**, Appelbaum, F.R., Beatty, P., Doney, K., Martin, P., Stewart, P., Sullivan, K.M., Witherspoon, R., Bensinger, W., Buckner, C.D., Clift, R., Hansen, J., Longton, G., Loughran, T., Petersen, F.B., Singer, J., Sanders, J., Thomas, E.D.: What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? *Blood* 76: 1037-1045, 1990.
  25. Beatty, P.G., Hansen, J.A., Longton, G.M., Thomas, E.D., Sanders, J.E., Martin, P.J., Bearman, S.I., **Anasetti, C.**, Petersdorf, E.W., Mickelson, E.M., Pepe, M.S., Appelbaum, F.R., Buckner, C.D., Clift, R.A., Petersen, F.B., Stewart, P.S., Storb, R.F., Sullivan, K.M., Tesler, M.C., Witherspoon, R.P.: Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. *Transplantation* 51: 443-447, 1991.
  26. **Anasetti, C.**, Martin, P.J., Storb, R., Appelbaum, F.R., Beatty, P.G., Calori, E., Davis, J., Doney, K., Reichert, T., Stewart, P., Sullivan, K.M., Thomas, E.D., Witherspoon, R.P., Hansen, J.A.: Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody-2A3. *Bone Marrow Transplantation* 7: 375-381, 1991.
  27. Doney, K., Fisher, L.D., Appelbaum, F.R., Buckner, C.D., Storb, R., Singer, J., Fefer, A., **Anasetti, C.**, Beatty, P., Bensinger, W., Clift, R., Hansen, J., Hill, R., Loughran, T.P., Jr., Martin, P., Petersen, F.B., Sanders, J., Sullivan, K.M., Stewart, P., Weiden, P., Witherspoon, R., Thomas, E.D.: Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. *Bone Marrow Transplant* 7: 453-459, 1991.
  28. Clift, R.A., Buckner, C.D., Appelbaum, F.R., Bryant, E., Bearman, S.I., Petersen, F.B., Fisher, L.D., **Anasetti, C.**, Beatty, P., Bensinger, W.I., Doney, K., Hill, R.S., McDonald, G.B., Martin, P., Meyers, J., Sanders, J., Singer, J., Stewart, P., Sullivan, K.M., Witherspoon, R., Storb, R., Hansen, J.A., Thomas, E.D.: Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens. *Blood* 77: 1660-1665, 1991.
  29. Stocksclaeder, M., Storb, R., Pepe, M., Longton, G., McDonald, G., **Anasetti, C.**, Appelbaum, F., Doney, K., Martin, P., Sullivan, K., Witherspoon, R.: A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. *Br. J. Haematol.* 80: 49-54, 1992.
  30. Doney, K., Pepe, M., Storb, R., Bryant, E., **Anasetti, C.**, Appelbaum, F.R., Buckner, C.D., Sanders, J., Singer, J., Sullivan, K., Weiden, P., Hansen, J.A.: Immunosuppressive therapy of aplastic anemia: Results of a prospective, randomized trial of antithymocyte globulin (ATG), methylprednisolone and oxymetholone to ATG, very high-dose methylprednisolone and oxymetholone. *Blood* 79: 2566-2571, 1992.
  31. Nemunaitis, J., **Anasetti, C.**, Storb, R., Bianco, J.A., Buckner, C.D., Onetto, N., Martin, P., Sanders, J., Sullivan, K., Mori, M., Shannon-Dorcy, K., Bowden, R., Appelbaum, F.R., Hansen, J., Singer, J.W.: Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. *Blood* 79: 2572-2577, 1992.
  32. **Anasetti, C.**, Martin, P.J., Storb, R., Appelbaum, F.R., Beatty, P.G., Davis, J., Doney, K., Hill, H.F., Stewart, P., Sullivan, K.M., Witherspoon, R.P., Thomas, E.D., Hansen, J.A.: Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. *Transplantation* 54: 844-851,



- 1992.
33. Nash, R.A., Pepe, M.S., Storb, R., Longton, G., Pettinger, M., **Anasetti, C.**, Appelbaum, F.R., Bowden, R., Deeg, H.J., Doney, K., Martin, P.J., Sullivan, K.M., Sanders, J., Witherspoon, R.P.: Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. *Blood* 80: 1838-1845, 1992.
  34. Linsley, P.S., Greene, J.L., Tan, P., Bradshaw, J., Ledbetter, J.A., **Anasetti, C.**, Damle, N.K.: Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. *J. Exp. Med* 176: 1595-1604, 1992. PMID:PMC2119471
  35. Beatty, P.G., **Anasetti, C.**, Hansen, J.A., Longton, G.M., Sanders, J.E., Martin, P.J., Mickelson, E.M., Choo, S.Y., Petersdorf, E.W., Pepe, M.S., Appelbaum, F.R., Bearman, S.I., Buckner, C.D., Clift, R.A., Petersen, F.B., Singer, J., Stewart, P.S., Storb, R.F., Sullivan, K.M., Tesler, M.C., Witherspoon, R.P., Thomas, E.D.: Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. *Blood* 81: 249-253, 1993.
  36. McGlave, P., Bartsch, G., **Anasetti, C.**, Ash, R., Beatty, P., Gajewski, J., Kernan, N.A.: Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. *Blood* 81: 543-550, 1993.
  37. Choo, S.Y., Starling, G.C., **Anasetti, C.**, Hansen, J.A.: Selection of an unrelated donor for marrow transplantation facilitated by the molecular characterization of a novel HLA-A allele. *Hum. Immunol* 36: 20-26, 1993.
  38. Tan, P., **Anasetti, C.**, Hansen, J.A., Melrose, J., Brunvand, M., Bradshaw, J., Ledbetter, J.A., Linsley, P.S.: Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB-1. *J. Exp. Med* 177: 165-173, 1993. PMID:PMC2190874
  39. Anderson, J.E., Appelbaum, F.R., Fisher, L.D., Schoch, G., Shulman, H., **Anasetti, C.**, Bensinger, W.I., Bryant, E., Buckner, C.D., Doney, K., Martin, P.J., Sanders, J.E., Sullivan, K.M., Thomas, E.D., Witherspoon, R.P., Hansen, J.A., Storb, R.: Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. *Blood* 82: 677-681, 1993.
  40. Weaver, C.H., Appelbaum, F.R., Petersen, F.B., Clift, R., Singer, J., Press, O., Bensinger, W., Bianco, J., Martin, P., **Anasetti, C.**, Badger, C., Deeg, J., Doney, K., Hansen, J.A., Petersdorf, E., Rowley, S., Storb, R., Sullivan, K., Witherspoon, R., Weiden, P., Buckner, C.D.: High-dose cyclophosphamide, carmustine and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. *J. Clin. Oncol* 11: 1329-1335, 1993.
  41. Voltarelli, J.C., Gjerset, G., **Anasetti, C.**: Adhesion of CD16+ K cells to antibody-coated targets is mediated by CD2 and CD18 receptors. *Immunol* 79: 509-511, 1993. PMID:PMC1421975
  42. Doney, K., Buckner, C.D., Fisher, L., Petersen, F.B., Sanders, J., Appelbaum, F.R., **Anasetti, C.**, Badger, C., Bensinger, W., Deeg, H.J., Fefer, A., Martin, P., Petersdorf, E., Schuening, F., Singer, J., Stewart, P., Storb, R., Sullivan, K.M., Witherspoon, R., Hansen, J.A.: Autologous bone marrow transplantation for acute lymphoblastic leukemia. *Bone Marrow Transplant* 12: 315-321, 1993.
  43. Petersdorf, E.W., Smith, A.G., Mickelson, E.M., Longton, G.M., **Anasetti, C.**, Choo, S.Y., Martin, P.J., Hansen, J.A.: The role of HLA-DPB1 disparity in the development of acute graft-versus-host disease following unrelated donor marrow transplantation. *Blood* 81: 1923-1932, 1993.
  44. Nemunaitis, J., **Anasetti, C.**, Bianco, J.A., Hansen, J., Singer, J.W.: rhGM-CSF after allogeneic bone marrow transplantation from unrelated donors: A pilot study of cyclosporine and prednisone as graft-versus-host disease prophylaxis. *Leukemia and Lymphoma* 10: 177-181, 1993.
  45. Bearman, S.I., Mori, M., Beatty, P.G., Meyer, W.G., Buckner, C.D., Petersen, F.B., Sanders, J.E., **Anasetti, C.**, Martin, P., Appelbaum, F.R., Hansen, J.A.: Comparison of morbidity and mortality after marrow transplantation from HLA-genotypically identical siblings and HLA-phenotypically identical unrelated donors. *Bone Marrow Transplant* 13: 31-35, 1994.
  46. Busca, A., **Anasetti, C.**, Anderson, G., Appelbaum, F.R., Buckner, C.D., Doney, K., Martin, P.J., Petersdorf, E., Sanders, J.E., Hansen, J.A.: Unrelated donor or autologous marrow transplantation for treatment of acute leukemia. *Blood* 83: 3077-3084, 1994.
  47. Storb, R., Etzioni, R., **Anasetti, C.**, Appelbaum, F.R., Buckner, C.D., Bensinger, W., Bryant, E., Clift, R., Deeg, H.J., Doney, K., Flowers, M., Hansen, J., Martin, P., Pepe, M., Sale, G., Sanders, J., Singer, J., Sullivan, K.M., Thomas, E.D., Witherspoon, R.P.: Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. *Blood* 84:

941-949, 1994.

48. **Anasetti, C.**, Hansen, J.A., Waldmann, T.A., Appelbaum, F.R., Davis, J., Deeg, H.J., Doney, K., Martin, P.J., Nash, R., Storb, R., Sullivan, K.M., Witherspoon, R.P., Binger, M.-H., Chizzonite, R., Hakimi, J., Mould, D., Satoh, H., Light, S.E.: Treatment of acute graft-versus-host disease with humanized anti-Tac: An antibody that binds to the interleukin-2 receptor. *Blood* 84: 1320-1327, 1994.
49. Clift, R.A., Buckner, C.D., Thomas, E.D., Bryant, E., **Anasetti, C.**, Bensinger, W.I., Bowden, R., Deeg, H.J., Doney, K.C., Fisher, L.D., Hansen, J.A., Martin, P., McDonald, G.B., Sanders, J.E., Schoch, G., Singer, J., Storb, R., Sullivan, K.M., Witherspoon, R.P., Appelbaum, F.R.: Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. *Blood* 84: 4368-4373, 1994.
50. Mickelson, E.M., Guthrie, L.A., Etzioni, R., **Anasetti, C.**, Martin, P.J., Hansen, J.A.: Role of the mixed lymphocyte culture (MLC) reaction in marrow donor selection: Matching for transplants from related haploidentical donors. *Tissue Antigens* 44: 83-92, 1994.
51. Balduzzi, A., Gooley, T., **Anasetti, C.**, Sanders, J.E., Martin, P.J., Petersdorf, E.W., Appelbaum, F.R., Buckner, C.D., Matthews, D., Storb, R., Sullivan, K.M., Hansen, J.A.: Unrelated donor marrow transplantation in children. *Blood* 86: 3247-3256, 1995.
52. Demirer, T., Weaver, C.H., Buckner, C.D., Petersen, F.B., Bensinger, W.I., Sanders, J., Clift, R.A., Lilleby, K., **Anasetti, C.**, Martin, P., Storb, R., Chauncey, T., Doney, K., Sullivan, K., Appelbaum, F.R.: High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. *J. Clin. Oncol.* 13: 596-602, 1995.
53. Nash, R.A., Etzioni, R., Storb, R., Furlong, T., Gooley, T., **Anasetti, C.**, Appelbaum, F.R., Doney, K., Martin, P., Slattery, J., Sullivan, K., Van Der Jagt, R., Witherspoon, R., Jusko, W.J., Zager, R.A., Deeg, H.J.: Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single-center study. *Blood* 85: 3746-3753, 1995.
54. Zhu, L., **Anasetti, C.**: Cell cycle control of apoptosis in human leukemic T cells. *J. Immunol* 154: 192-200, 1995.
55. Slattery, J.T., Sanders, J.E., Buckner, C.D., Schaffer, R.L., Lambert, K.W., Langer, F.P., **Anasetti, C.**, Bensinger, W.I., Fisher, L.D., Appelbaum, F.R., Hansen, J.A.: Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. *Bone Marrow Transplant* 16: 31-42, 1995.
56. Doney, K.C., Storb, R., Beach, K., **Anasetti, C.**, Deeg, H.J., Hansen, J.A., Martin, P.J., Nash, R.A., Schubert, M.M., Sullivan, K.M., Witherspoon, R.P., Appelbaum, F.R.: A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants. *Transplantation* 60: 55-58, 1995.
57. Petersdorf, E.W., Longton, G.M., **Anasetti, C.**, Martin, P.J., Mickelson, E.M., Smith, A.G., Hansen, J.A.: The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. *Blood* 86: 1606-1613, 1995.
58. Walker, J.V., Morich, D., **Anasetti, C.**: Minimal-change nephrotic syndrome after cyclosporine withdrawal in a marrow transplant recipient. *Am. J. Kidney Dis.* 26: 532-534, 1995.
59. Mickelson, E.M., Longton, G., **Anasetti, C.**, Petersdorf, E., Martin, P., Guthrie, L.A., Hansen, J.A.: Evaluation of the mixed lymphocyte culture (MLC) assay as a method for selecting unrelated donors for marrow transplantation. *Tissue Antigens* 47: 27-36, 1996.
60. Anderson, J.E., Appelbaum, F.R., Schoch, G., Gooley, T., **Anasetti, C.**, Bensinger, W.I., Bryant, E., Buckner, C.D., Chauncey, T., Clift, R.A., Deeg, H.J., Doney, K., Flowers, M., Hansen, J.A., Martin, P.J., Matthews, D.C., Nash, R.A., Sanders, J.E., Shulman, H., Sullivan, K.M., Witherspoon, R.P., Storb, R.: Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. *J. Clin. Oncol* 14: 220-226, 1996.
61. Anderson, J.E., Appelbaum, F.R., Schoch, G., Gooley, T., **Anasetti, C.**, Bensinger, W.I., Bryant, E., Buckner, C.D., Chauncey, T.R., Clift, R.A., Doney, K., Flowers, M., Hansen, J.A., Martin, P.J., Matthews, D.C., Sanders, J.E., Shulman, H., Sullivan, K.M., Witherspoon, R.P., Storb, R.: Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors. *Blood* 87: 51-58, 1996.
62. Wagner, J.L., Deeg, H.J., Seidel, K., **Anasetti, C.**, Doney, K., Sanders, J., Sullivan, K.M., Storb, R.: Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives:

- An update of the Seattle experience. *Transplantation* 61: 54-61, 1996.
63. Langston, A.A., Sanders, J.E., Deeg, H.J., Crawford, S.W., **Anasetti, C.**, Sullivan, K.M., Flowers, M.E.D., Storb, R.: Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. *Br. J. Haematol.* 92: 758-765, 1996.
  64. Sullivan, K.M., Storek, J., Kopecky, K.J., Jocom, J., Longton, G., Flowers, M., Siadak, M., Nims, J., Witherspoon, R.P., **Anasetti, C.**, Appelbaum, F.R., Bowden, R.A., Buckner, C.D., Crawford, S.W., Deeg, H.J., Hansen, J.A., McDonald, G.B., Sanders, J.E., Storb, R.: A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: Clinical outcome and effect on subsequent immune recovery. *Biol. Blood and Marrow Transplant* 2: 44-53, 1996.
  65. Anderson, J.E., **Anasetti, C.**, Appelbaum, F.R., Schoch, G., Gooley, T.A., Hansen, J.A., Buckner, C.D., Sanders, J.E., Sullivan, K.M., Storb, R.: Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. *Br. J. Haematol.* 93: 59-67, 1996.
  66. Martin, P.J., Nelson, B.J., Appelbaum, F.R., **Anasetti, C.**, Deeg, H.J., Hansen, J.A., McDonald, G.B., Nash, R.A., Sullivan, K.M., Witherspoon, R.P., Scannon, P.J., Friedmann, N., Storb, R.: Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. *Blood* 88: 824-830, 1996.
  67. Rondelli, D., Andrews, R.G., Hansen, J.A., Ryncarz, R., Faerber, M.A., **Anasetti, C.**: Alloantigen presenting function of normal human CD34+ hematopoietic cells. *Blood* 88: 2619-2625, 1996.
  68. Yu, X.-Z., Zhu, L., Davis, J.E., Tso, J.Y., Hansen, J.A., **Anasetti, C.**: Induction of apoptosis by anti-CD3 F(AB')<sub>2</sub> in antigen receptor transgenic murine T cells activated by specific peptide. *J. Immunol* 157: 3420-3429, 1996.
  69. Bensinger, W.I., Buckner, C.D., **Anasetti, C.**, Clift, R., Storb, R., Barnett, T., Chauncey, T., Shulman, H., Appelbaum, F.R.: Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome. *Blood* 88: 2787-2793, 1996.
  70. Nash, R.A., Pineiro, L.A., Storb, R., Deeg, H.J., Fitzsimmons, W.E., Furlong, T., Hansen, J.A., Gooley, T., Maher, R.M., Martin, P., McSweeney, P.A., Sullivan, K.M., **Anasetti, C.**, Fay, J.W.: FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. *Blood* 88: 3634-3641, 1996.
  71. Slattery, J.T., Kalhorn, T.F., McDonald, G.B., Lambert, K., Buckner, C.D., Bensinger, W.I., **Anasetti, C.**, Appelbaum, F.R.: Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. *J. Clin. Oncol* 14: 1484-1494, 1996.
  72. Petersdorf, E.W., Longton, G.M., **Anasetti, C.**, Mickelson, E.M., Smith, A.G., Martin, P.J., Hansen, J.A.: Definition of HLA-DQ as a transplantation antigen. *Proc. Natl. Acad. Sci. USA* 93: 15358-15363, 1996. PMID:PMC26409
  73. McCarthy, P.L., Jr., Williams, L., Harris-Bacile, M., Yen, J., Przepiorka, D., Ippoliti, C., Champlin, R., Fay, J., Bloesch, C., Jacobs, C., **Anasetti, C.**: A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease. *Transplantation* 62: 626-631, 1996.
  74. Anderson, J.E., Gooley, T.A., Schoch, G., **Anasetti, C.**, Bensinger, W.I., Clift, R.A., Hansen, J.A., Sanders, J.E., Storb, R., Appelbaum, F.R.: Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. *Blood* 89: 2578-2585, 1997.
  75. Slattery, J.T., Clift, R.A., Buckner, C.D., Radich, J., Storer, B., Bensinger, W.I., Soll, E., **Anasetti, C.**, Bowden, R., Bryant, E., Chauncey, T., Deeg, H.J., Doney, K.C., Flowers, M., Gooley, T., Hansen, J.A., Martin, P.J., McDonald, G.B., Nash, R., Petersdorf, E.W., Sanders, J.E., Schoch, G., Stewart, P., Storb, R., Sullivan, K.M., Thomas, E.D., Witherspoon, R.P., Appelbaum, F.R.: Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. *Blood* 89: 3055-3060, 1997.
  76. Deeg, H.J., Lin, D., Leisenring, W., Boeckh, M., **Anasetti, C.**, Appelbaum, F.R., Chauncey, T.R., Doney, K., Flowers, M., Martin, P., Nash, R., Schoch, G., Sullivan, K.M., Witherspoon, R.P., Storb, R.: Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. *Blood* 89: 3880-3887, 1997.
  77. Sierra, J., Storer, B., Hansen, J.A., Bjerke, J.W., Martin, P.J., Petersdorf, E.W., Appelbaum, F.R., Bryant, E., Chauncey, T.R., Sale, G., Sanders, J.E., Storb, R., Sullivan, K.M., **Anasetti, C.** :

- Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching and marrow cell dose. *Blood* 89: 4226-4235, 1997.
78. Petersdorf, E.W., Longton, G.M., **Anasetti, C.**, Mickelson, E.M., McKinney, S.K., Smith, A.G., Martin, P.J., Hansen, J.A.: Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. *Blood* 89: 1818-1823, 1997.
  79. Sierra, J., Radich, J., Hansen, J.A., Martin, P.J., Petersdorf, E.W., Bjerke, J., Bryant, E., Nash, R.A., Sanders, J.E., Storb, R., Sullivan, K.M., Appelbaum, F.R., **Anasetti, C.**: Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. *Blood* 90: 1410-1414, 1997.
  80. Storb, R., Leisenring, W., **Anasetti, C.**, Appelbaum, F.R., Deeg, H.J., Doney, K., Martin, P., Sullivan, K.M., Witherspoon, R., Pettinger, M., Bensinger, W., Buckner, C.D., Clift, R., Flowers, M.E.D., Hansen, J.A., Pepe, M., Chauncey, T., Sanders, J., Thomas, E.D.: Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine? *Biol. Blood Marrow Transplant* 3: 194-201, 1997.
  81. Pei, J., Martin, P.J., Longton, G., Masewicz, S., Mickelson, E., Petersdorf, E., **Anasetti, C.**, Hansen, J.: Evaluation of pretransplant donor anti-recipient cytotoxic and helper T lymphocyte responses as correlates of acute graft-vs-host disease and survival after unrelated marrow transplantation. *Biol. Blood Marrow Transplant* 3: 142-149, 1997.
  82. Martin, P.J., Petersdorf, E.W., **Anasetti, C.**, Hansen, J.A.: HLA homozygosity and the risk of graft-versus-host disease. *Tissue Antigens* 50: 119-123, 1997.
  83. Cole, M.S., **Anasetti, C.**, Tso, J.Y.: Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. *J. Immunol.* 159: 3613-3621, 1997.
  84. Martin, P., Nash, R., Sanders, J., Leisenring, W., **Anasetti, C.**, Deeg, H.J., Storb, R., Appelbaum, F.: Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation. *Bone Marrow Transplant* 21: 273-279, 1998.
  85. Rondelli, D., **Anasetti, C.**, Fortuna, A., Ratta, M., Arpinati, M., Bandini, G., Lemoli, R.M., Tura, S.: T cell alloreactivity induced by normal G-CSF-mobilized CD34+ blood cells. *Bone Marrow Transplant.* 21: 1183-1191, 1998.
  86. Hansen, J.A., Gooley, T.A., Martin, P.J., Appelbaum, F., Chauncey, T.R., Clift, R.A., Petersdorf, E.W., Radich, J., Sanders, J.E., Storb, R.F., Sullivan, K.M., **Anasetti, C.** Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. *New England Journal of Medicine* 338: 962-968, 1998.
  87. Ryncarz, R.E., **Anasetti, C.**: Expression of CD86 on human marrow CD34+ cells identifies immunocompetent committed precursors of macrophages and dendritic cells. *Blood* 91: 3892-3900, 1998.
  88. Woolfrey, A.E., Gooley, T.A., Sievers, E.L., Milner, L.A., Andrews, R.G., Walters, M., Hoffmeister, P., Hansen, J.A., **Anasetti, C.**, Bryant, E., Appelbaum, F.R., Sanders, J.E. Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome. *Blood* 92: 3546-3556, 1998.
  89. Morton, A.J., Gooley, T., Hansen, J.A., Appelbaum, F.R., Bruemmer, B., Bjerke, J.W., Clift, R., Martin, P.J., Petersdorf, E.W., Sanders, J.E., Storb, R., Sullivan, K.M., Woolfrey, A., **Anasetti, C.** Association between pretransplant interferon- $\alpha$  and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. *Blood* 92: 394-401, 1998.
  90. Stucki, A., Leisenring, W., Sandmaier, B.M., Sanders, J., **Anasetti, C.**, Storb, R.: Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis). *Blood* 92: 2742-2749, 1998.
  91. Ren, S., Kalhorn, T.F., McDonald, G.B., **Anasetti, C.**, Appelbaum, F.R., Slattery, J.T.: Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. *Clin. Pharmacol. Ther* 64: 289-301, 1998.
  92. Petersdorf, E.W., Gooley, T.A., **Anasetti, C.**, Martin, P.J., Smith, A.G., Mickelson, E.M., Woolfrey, A.E., Hansen, J.A.: Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. *Blood* 92: 3515-3520, 1998.
  93. Lee, S.J., **Anasetti, C.**, Kuntz, K.M., Patten, J., Antin, J.H., Weeks, J.C.: The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. *Blood* 92: 4047-4052, 1998.
  94. Yu, X.-Z., Martin, P.J., **Anasetti, C.**: Role of CD28 in acute graft-versus-host disease. *Blood* 92: 2963-

2970, 1998.

95. Rondelli, D., Raspadori, D., **Anasetti, C.**, Bandini, G., Re, F., Arpinati, M., Stanzani, M., Morelli, A., Baccini, C., Zaccaria, A., Lemoli, R.M., Tura, S.: Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. *Bone Marrow Transplant* 22: 631-637, 1998.
96. Martin, P.J., Gooley, T., **Anasetti, C.**, Petersdorf, E.W., Hansen, J.A.: HLAs and risk of acute graft-vs.-host disease after marrow transplantation from an HLA-identical sibling. *Biol. Blood and Marrow Transplant* 4: 128-133, 1998.
97. Zhu, L., Yu, X., Akatsuka, Y., Cooper, J.A., **Anasetti, C.**: Role of mitogen-activated protein kinases in activation-induced apoptosis of T cells. *Immunology* 97: 26-35, 1999. PMID:PMC2326808
98. Deeg, H.J., Seidel, K., Casper, J., **Anasetti, C.**, Davies, S., Gajewski, J.L., Territo, M., Ramsay, N., Harris, R.E., Castro-Malaspina, H., Collins, R., Champlin, R., Schoch, G., King, R., Howe, C.: Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. *Biol. Blood Marrow Transplant* 5: 243-252, 1999.
99. Cole, M.S., Stellrecht, K.E., Shi, J.D., Homola, M., Hsu, D.-H., **Anasetti, C.**, Vasquez, M., Tso, J.Y.: HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. *Transplantation* 68: 563-571, 1999.
100. Martin, P.J., Rowley, S.D., **Anasetti, C.**, Chauncey, T.R., Gooley, T., Petersdorf, E.W., van Burik, J.-A., Flowers, M.E.D., Storb, R., Appelbaum, F.R., Hansen, J.A.: A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. *Blood* 94: 2192-2199, 1999.
101. Yu, X.-Z., Bidwell, S., Martin, P.J., **Anasetti, C.**: Visualization, fate and pathogenicity of antigen-specific CD8<sup>+</sup>T cells in the graft-versus-host reaction. *J. Immunol* 163: 4780-4787, 1999.
102. Matsumoto, K., **Anasetti, C.**: The role of T cell costimulation by CD80 in the initiation and maintenance of immune response to human leukemia. *Leuk. Lymphoma* 35: 427-435, 1999.
103. Feinstein, L.C., Seidel, K., Jocum, J., Bowden R.A., **Anasetti, C.**, Deeg, H.J., Flowers, M.E.D., Kansu, E., Martin, P.J., Nash, R.A., Storek, J., Etzioni, R., Appelbaum, F.R., Hansen, J.A., Storb, R., Sullivan, K.M.: Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. *Biol. Blood. Marrow. Transplant.* 5: 369-378, 1999.
104. Yu, X.-Z., **Anasetti, C.**: Enhancement of susceptibility to Fas-mediated apoptosis of TH1 cells by nonmitogenic anti-CD3 F(ab')<sub>2</sub>. *Transplantation* 69: 104-112, 2000.
105. Arpinati, M., Green, C.L., Heimfeld, S., Heuser, J.E., **Anasetti, C.**: Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. *Blood* 95: 2484-2490, 2000.
106. Deeg, H.J., Shulman, H.M., Anderson, J.E., Bryant, E.M., Gooley, T.A., Slattery, J.T., **Anasetti, C.**, Fefer, A., Storb, R., Appelbaum, F.R.: Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. *Blood* 95: 1188-1194, 2000.
107. McGlave, P.B., Shu, X.O., Wen, W., **Anasetti, C.**, Nademanee, A., Champlin, R., Antin, J.H., Kernan, N.A., King, R., Weisdorf, D.J.: Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program. *Blood* 95: 2219-2225, 2000.
108. Zang, D.Y., Deeg, H.J., Gooley, T., Anderson, J.E., **Anasetti, C.**, Sanders, J., Myerson, D., Storb, R., Appelbaum, F. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. *Br. J. Haematol* 110: 217-222, 2000.
109. Nash, R.A., Antin, J.H., Karanes, C., Fay, J.W., Avalos, B.R., Yeager, A.M., Przepiorka, D., Davies, S., Petersen, F.B., Bartels, P., Buell, D., Fitzsimmons, W., **Anasetti, C.**, Storb, R., Ratanatharathorn, V. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. *Blood* 96: 2062-2068, 2000.
110. Yu, X.Z., Bidwell, S.J., Martin, P.J., **Anasetti, C.** CD28-specific antibody prevents graft-versus-host disease in mice. *J. Immunol.* 164: 4564-4568, 2000.
111. Flowers, M.E.D., Leisenring, W., Beach, K., Riddell, S., Radich, J.P., Higano, C., Rowley, S.D., Chauncey, T.R., Bensinger, W.I., Sanders, J.E., **Anasetti, C.**, Storb, R., Wade, J., Appelbaum, F.R., Martin, P.J. Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. *Biol. Blood Marrow Transplant* 6: 321-326, 2000.
112. Koc, S., Leisenring, W., Flowers, M.E.D., **Anasetti, C.**, Deeg, H.J., Nash, R.A., Sanders, J.E., Witherspoon, R.P., Appelbaum, F.R., Storb, R., Martin, P.J. Thalidomide for treatment of patients with

- chronic graft-versus-host disease. *Blood* 96: 3995-3996, 2000.
113. Furlong, T., Storb, R., **Anasetti, C.**, Appelbaum, F.R., Deeg, H.J., Doney, K., Martin, P., Sullivan, K., Witherspoon, R., Nash, R.A. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. *Bone Marrow Transplant* 26: 985-991, 2000.
  114. Ohishi, K., Varnum-Finney, B., Flowers, D., **Anasetti, C.**, Myerson, D., Bernstein, I.D. Monocytes express high amounts of Notch and undergo cytokine specific apoptosis following interaction with the Notch ligand, Delta-1. *Blood* 95: 2847-2854, 2000.
  115. Sierra, J., Storer, B., Hansen, J.A., Martin, P.J., Petersdorf, E.W., Woolfrey, A., Matthews, D., Sanders, J.E., Storb, R., Appelbaum, F.R., **Anasetti, C.** Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. *Bone Marrow Transplant* 26: 397-404, 2000.
  116. Carnevale-Schianca, F., Martin, P., Sullivan, K., Flowers, M., Gooley, T., **Anasetti, C.**, Deeg, J., Furlong, T., McSweeney, P., Storb, R., Nash, R.A. Changing cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. *Biol. Blood. Marrow. Transplant.* 6: 613-620, 2000.
  117. Carpenter, P.A., Pavlovic, S., Tso, J.Y., Press, O.W., Gooley, T., Yu, X.-Z., **Anasetti, C.** Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. *The J. Immunol* 165: 6205-6213, 2000.
  118. Jurado, M., Deeg, H.J., Gooley, T., **Anasetti, C.**, Chauncey, T., Flowers, M.E.D., Myerson, D., Storb, R., Appelbaum, F.R. Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia. *Br. J. Haematol* 112: 392-396, 2001.
  119. Radich, J.P., Gooley, T., Sanders, J.E., **Anasetti, C.**, Chauncey, T., Appelbaum, F.R. Second allogeneic transplantation after failure of first autologous transplantation. *Biol. Blood Marrow Transplant* 6: 272-279, 2000.
  120. Deeg, H.J., Amylon, M.D., Harris, R.E., Collins, R., Beatty, P.G., Feig, S., Ramsay, N., Territo, M., Khan, S.P., Pamphilon, D., Leis, J.F., Burdach, S., **Anasetti, C.**, Hackman, R., Storer, B., Mueller, B. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. *Biol. Blood Marrow Transplant* 7: 208-215, 2001.
  121. Witherspoon, R.P., Deeg, H.J., Storer, B., **Anasetti, C.**, Storb, R., Appelbaum, F.R. Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. *J. Clin. Oncol* 19: 2134-2141, 2001.
  122. Cornelissen, J.J., Carston, M., Kollman, C., King, R., Dekker, A.W., Löwenberg, B., **Anasetti, C.** Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. *Blood* 97: 1572-1577, 2001.
  123. Davies, S.M., Kollman, C., **Anasetti, C.**, Antin, J.H., Gajewski, J., Casper, J.T., Nademanee, A., Noreen, H., King, R., Confer, D., Kernan, N.A. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program. *Blood* 96: 4096-4102, 2000.
  124. Petersdorf, E.W., Gooley, T., Malkki, M., **Anasetti, C.**, Martin, P., Woolfrey, A., Smith, A., Mickelson, E., Hansen, J.A. The biological significance of HLA-DP gene variation in haematopoietic cell transplantation. *Br. J. Haematol* 112: 988-994, 2001.
  125. Pei, J., Akatsuka, Y., **Anasetti, C.**, Lin, M.-T., Petersdorf, E.W., Hansen, J.A., Martin, P.J. Generation of HLA-C-specific cytotoxic T cells in association with marrow graft rejection: analysis of alloimmunity by T-cell cloning and testing of T-cell-receptor rearrangements. *Biol. Blood and Marrow Transplant* 7: 378-383, 2001.
  126. Benito, A.I., Furlong, T., Martin, P.J., **Anasetti, C.**, Appelbaum, F.R., Doney, K., Nash, R.A., Papayannopoulou, T., Storb, R., Sullivan, K.M., Witherspoon, R., Deeg, H.J. Sirolimus (Rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. *Transplantation* 72: 1924-1929, 2001.
  127. Zerr, D.M., Gooley, T.A., Yeung, L., Huang, M.-L., Carpenter, P., Wade, J.C., Corey, L., **Anasetti, C.** Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients. *Clin. Infect. Dis* 33: 763-771, 2001.
  128. Lee, S.J., Klein, J.P., **Anasetti, C.**, Antin, J.H., Loberiza, F.R., Bolwell, B.J., LeMaistre, C.F., Litzow, M.R., Marks, D., Waller, E.K., Matlack, M., Giral, S., Horowitz, M.M. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. *Blood* 98: 3205-3211, 2001.

129. Kansu, E., Gooley, T., Flowers, M.E.D., **Anasetti, C.**, Deeg, H.J., Nash, R.A., Sanders, J.E., Witherspoon, R.P., Appelbaum, F.R., Storb, R., Martin, P.J. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial (Brief Report). *Blood* 98: 3868-3870, 2001.
130. Woolfrey, A.E., **Anasetti, C.**, Storer, B., Doney, K., Milner, L.A., Sievers, E.L., Carpenter, P., Martin, P., Petersdorf, E., Appelbaum, F.R., Hansen, J.A., Sanders, J.E. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. *Blood* 99: 2002-2008, 2002.
131. Carpenter, P.A., Appelbaum, F.R., Corey, L., Deeg, H.J., Doney, K., Gooley, T., Krueger, J., Martin, P., Pavlovic, S., Sanders, J., Slattery, J., Levitt, D., Storb, R., Woolfrey, A., **Anasetti, C.** A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. *Blood* 99: 2712-2719, 2002.
132. Petersdorf, E.W., Hansen, J.A., Martin, P.J., Woolfrey, A., Malkki, M., Gooley, T., Storer, B., Mickelson, E., Smith, A., **Anasetti, C.** Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. *N. Engl. J. Med* 345: 1794-1800, 2001.
133. Jurado, M., Deeg, H.J., Storer, B., **Anasetti, C.**, Anderson, J.E., Bryant, E., Chauncey, T., Doney, K., Flowers, M.E.D., Hansen, J., Martin, P.J., Nash, R.A., Petersdorf, E., Radich, J., Sale, G., Sandmaier, B.M., Storb, R., Wade, J., Witherspoon, R., Appelbaum, F.R. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. *Biol. Blood Marrow Transplant* 8: 161-169, 2002.
134. Kollman, C., Howe, C.W.S., **Anasetti, C.**, Antin, J.H., Davies, S.M., Filipovich, A.H., Hegland, J., Kamani, N., Kernan, N.A., King, R., Ratanatharathorn, V., Weisdorf, D., Confer, D.L. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. *Blood* 98: 2043-2051, 2001.
135. Ohishi, K., Varnum-Finney, B., Serda, R.E., **Anasetti, C.**, Bernstein, I.D. The notch ligand, delta-1, inhibits the differentiation of monocytes into macrophages but permits their differentiation into dendritic cells. *Blood* 98: 1402-1407, 2001.
136. Yu, X.-Z., Bidwell, S.J., Martin, P.J., **Anasetti, C.** Anti-CD3 F(ab')<sub>2</sub> prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens. *J. Immunol* 166: 5835-5839, 2001.
137. Remberger, M., Storer, B., Ringden, O., **Anasetti, C.** Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. *Bone Marrow Transplant* 29: 391-397, 2002.
138. Weisdorf, D.J., **Anasetti, C.**, Antin, J.H., Kernan, N.A., Kollman, C., Snyder, D., Petersdorf, E., Nelson, G., McGlave, P. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. *Blood* 99: 1971-1977, 2002.
139. Furlong, T., Leisenring, W., Storb, R., **Anasetti, C.**, Appelbaum, F.R., Carpenter, P.A., Deeg, H.J., Doney, K., Kiem, H.-P., Nash, R.A., Sanders, J.E., Witherspoon, R., Thompson, D., Martin, P.J. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. *Biol. Blood and Marrow Transplant* 8: 206-212, 2002.
140. Koc, S., Leisenring, W., Flowers, M.E.D., **Anasetti, C.**, Deeg, H.J., Nash, R.A., Sanders, J.E., Witherspoon, R.P., Storb, R., Appelbaum, F.R., Martin, P.J. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. *Blood* 100: 48-51, 2002.
141. Deeg, H.J., Storer, B., Slattery, J.T., **Anasetti, C.**, Doney, K.C., Hansen, J.A., Kiem, H.-P., Martin, P.J., Petersdorf, E., Radich, J.P., Sanders, J.E., Shulman, H.M., Warren, E.H., Witherspoon, R.P., Bryant, E.M., Chauncey, T.R., Getzendaner, L., Storb, R., Appelbaum, F.R. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. *Blood* 100: 1201-1207, 2002.
142. McCune, J.S., Gooley, T., Gibbs, J.P., Sanders, J.E., Petersdorf, E.W., Appelbaum, F.R., **Anasetti, C.**, Risler, L., Sultan, D., Slattery, J.T. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. *Bone Marrow Transplant* 30: 167-173, 2002.
143. Tan, P., Mitchell, D.A., Buss, T.N., Holmes, M.A., **Anasetti, C.**, Foote, J. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human

- germline sequences: application to an anti-CD28. *J. Immunol* 169: 1119-1125, 2002.
144. Chen, C.-S., Boeckh, M., Seidel, K., Clark, J.G., Kansu, E., Madtes, D.K., Wagner, J.L., Witherspoon, R.P., **Anasetti, C.**, Appelbaum, F.R., Bensinger, W.I., Deeg, H.J., Martin, P.J., Sanders, J.E., Storb, R., Storek, J., Wade, J., Siadak, M., Flowers, M.E.D., Sullivan, K.M. Incidence, risk factors and mortality from pneumonia developing late after hematopoietic stem cell transplantation. *Bone Marrow Transplant* 32: 515-522, 2003.
  145. McDonald, G.B., Slattery, J.T., Bouvier, M.E., Ren, S., Batchelder, A.L., Kalhorn, T.F., Schoch, H.G., **Anasetti, C.**, Gooley, T. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. *Blood* 101: 2043-2048, 2003.
  146. Niederwieser, D., Maris, M., Shizuru, J.A., Petersdorf, E., Hegenbart, U., Sandmaier, B.M., Maloney, D.G., Storer, B., Lange, T., Chauncey, T., Deininger, M., Pönisch, W., **Anasetti, C.**, Woolfrey, A., Little, M.-T., Blume, K.G., McSweeney, P.A., Storb, R.F. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. *Blood* 101: 1620-1629, 2003.
  147. Yu, X.-Z., Martin, P.J., **Anasetti, C.** CD28 signal enhances apoptosis of CD8 T cells after strong TCR ligation. *J. Immunol* 170: 3002-3006, 2003.
  148. Bornhäuser, M., Storer, B., Slattery, J.T., Appelbaum, F.R., Deeg, H.J., Hansen, J., Martin, P.J., McDonald, G.B., Nichols, G., Radich, J., Woolfrey, A., Jenke, A., Schleyer, E., Thiede, C., Ehninger, G., **Anasetti, C.** Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. *Blood* 102: 820-826, 2003.
  149. Maris, M.B., Niederwieser, D., Sandmaier, B.M., Storer, B., Stuart, M., Maloney, D., Petersdorf, E., McSweeney, P., Pulsipher, M., Woolfrey, A., Chauncey, T., Agura, E., Heimfeld, S., Slattery, J., Hegenbart, U., **Anasetti, C.**, Blume, K., Storb, R. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. *Blood* 102: 2021-2030, 2003.
  150. Deeg, H.J., Gooley, T.A., Flowers, M.E.D., Sale, G.E., Slattery, J.T., **Anasetti, C.**, Chauncey, T.R., Doney, K., Georges, G.E., Kiem, H.-P., Martin, P.J., Petersdorf, E.W., Radich, J., Sanders, J.E., Sandmaier, B.M., Warren, E.H., Witherspoon, R.P., Storb, R., Appelbaum, F.R. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. *Blood* 102: 3912-3918, 2003.
  151. Martin, P.J., McDonald, G.B., Sanders, J.E., **Anasetti, C.**, Appelbaum, F.R., Deeg, H.J., Nash, R.A., Petersdorf, E.W., Hansen, J.A., Storb, R. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. *Biol. Blood Marrow Transplant* 10: 320-7, 2004.
  152. Yu, X.-Z., Levin, S.D., Madrenas, J., **Anasetti, C.** Lck is required for activation-induced T cell death after TCR ligation with partial agonists. *J. Immunol.* 172: 1437-1443, 2004.
  153. Yusuf, U., Frangoul, H.A., Gooley, T.A., Woolfrey, A.E., Carpenter, P.A., Andrews, R.G., Deeg, H.J., Appelbaum, F.R., **Anasetti, C.**, Storb, R., Sanders, J.E. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. *Bone Marrow Transplant* 33: 805-14, 2004.
  154. Cutler, C.S., Lee, S.J., Greenberg, P., Deeg, H.J., Pérez, W.S., **Anasetti, C.**, Bolwell, B.J., Cairo, M.S., Gale, R.P., Klein, J.P., Lazarus, H.M., Liesveld, J.L., McCarthy, P.L., Milone, G.A., Rizzo, J.D., Schultz, K.R., Trigg, M.E., Keating, A., Weisdorf, D.J., Antin, J.H., Horowitz, M.M. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low risk myelodysplasia is associated with improved outcome. *Blood* 104: 579-585, 2004
  155. Martin, P.J., Pei, J., Gooley, T., **Anasetti, C.**, Appelbaum, F.R., Deeg, J., Hansen, J.A., Nash, R.A., Petersdorf, E.W., Storb, R., Ghetie, V., Schindler, J., Vitetta, E.S. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. *Biol. Blood Marrow Transplant* 10: 552-560, 2004.
  156. Yu, X.Z., Albert M.H., Martin P.J., **Anasetti C.** CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens. *J. Clin. Invest.* 113:1624-30, 2004. PMC419490
  157. Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA, Appelbaum FR, Carpenter PA, Sanders JE, Kiem HP, Nash RA, Petersdorf EW, Moravec C, Morton AJ, **Anasetti C**, Flowers ME, Martin PJ. Duration of immunosuppressive treatment for chronic graft-versus-host disease. *Blood* 104:3501-6,



- 2004.
158. Petersdorf EW, **Anasetti C**, Martin PJ, Gooley T, Radich J, Malkki M, Woolfrey A, Smith A, Mickelson E, Hansen JA. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. *Blood* 104:2976-8, 2004.
  159. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M, Hurley C, Kollman C, **Anasetti C**, Noreen H, Begovich A, Hildebrand W, Petersdorf E, Schmeckpeper B, Setterholm M, Trachtenberg E, Williams T, Yunis E, Weisdorf D. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. *Blood* 104:1923-30, 2004.
  160. Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P, Jerome KR, McCune JS, Storer B, Martin P, Appelbaum F, Abonour R, Westervelt P, **Anasetti C**. A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid-Refractory Acute Graft-versus-Host Disease. *Biol. Blood Marrow Transplant* 11:465-71, 2005.
  161. Albert MH, Yu XZ, Martin PJ, **Anasetti C**. Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin. *Blood* 105:1355-61, 2005.
  162. Albert MA, Liu Y, **Anasetti C**, Yu, XZ. Antigen-dependent suppression of alloresponses by Foxp3-induced regulatory T cells in transplantation. *Eur J Immunol* 35:2598-2607, 2005.
  163. Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giral S, Molina A, Copelan EA, Ringden O, Roy V, Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, **Anasetti C**. Unrelated Donor Marrow Transplantation for B-Cell Chronic Lymphocytic Leukemia After Using Myeloablative Conditioning: Results From the Center for International Blood and Marrow Transplant Research. *J. Clin. Oncol* 23:5788-94, 2005.
  164. Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT, Furlong T, **Anasetti C**, Appelbaum FR, Lloid ME, Deeg HJ, Kiem HP, Martin PJ, Schubert MM, Witherspoon RP, Forman SJ, Blume KG, Storb R. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. *Biol. Blood Marrow Transplant* 11:495-505, 2005.
  165. Yu, XZ, Albert, MH, **Anasetti, C**. Alloantigen affinity and CD4 help determine severity of graft-versus-host disease mediated by CD8 donor T cells. *J Immunol* 176:3383-90, 2006.
  166. Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D, Heimfeld S, Flowers ME, **Anasetti C**, Doney KC, Hansen JA, Kiem HP, Nash RA, O'Donnell PV, Radich JP, Sandmaier BM, Scott BL, Sorrow ML, Warren EH, Witherspoon RP, Woolfrey A, Appelbaum FR, Storb R. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. *Biol. Blood Marrow Transplant* 12:573-84, 2006.
  167. Yu XZ, Liang Y, Nurieva RI, Guo F, **Anasetti C**, Dong C. Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cells. *J. Immunol* 15: 176:7394-401, 2006.
  168. Green MR, **Anasetti C**, Sandin RL, Rolfe NE, Greene NJ. Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant *Enterococcus durans*. *J Oncol Pharm Practice* 12: 179-181, 2006.
  169. Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA, Boudreau C, Nelson G, Oudshoorn M, van Rood J, Velardi A, Maiers M, Setterholm M, Confer D, Posch PE, **Anasetti C**, Kamani N, Miller JS, Weisdorf D, Davies SM, KIR Study Group, Center for International Blood and Marrow Transplantation Research. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. *Biol. Blood Marrow Transplant* 12:876-84, 2006.
  170. Jacobs SR, Jacobsen PB, Booth-Jones M, Wagner LI, **Anasetti C**. Evaluation of the Functional Assessment of Cancer Therapy Cognitive Scale with Hematopoietic Stem Cell Transplant Patients. *Journal of Pain and Symptom Management* 33: 13-23, 2007.
  171. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, Fernandez-Vina M, Flomenberg N, Horowitz M, Hurley CK, Noreen H, Oudshoorn M, Petersdorf E, Setterholm M, Spellman S, Weisdorf D, Williams TM, **Anasetti C**. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. *Blood* 110:4576-83, 2007.
  172. Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ, Wingard JR, Rowley SD, Stroneck D, Gee AP, Horowitz MM, **Anasetti C**. Peripheral blood grafts from unrelated donors are

- associated with increased acute and chronic graft-versus-host disease without improved survival. *Biol. Blood Marrow Transplant* 13:1461-8, 2007. PMC2267869
173. Liang Y, Liu C, Djeu JY, Zhong B, Peters T, Scharffetter-Kochanek K, **Anasetti C**, Yu XZ. Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects. *Blood* 111:954-62, 2008. PMC2200850
  174. Perez LE, Parquet N, Shain K, Nimmanapalli R, Alsina M, **Anasetti C**, Dalton W. Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP. *J Immunol* 180:1545-55, 2008.
  175. Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, **Anasetti C**, Setterholm M, Drexler R, Maiers M, King R, Confer D, Klein J: Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. *Biol. Blood Marrow Transplant* 14:748-58, 2008. PMC2668157
  176. Hahn T, McCarthy PL Jr, Zhang MJ, Wang D, Arora M, Frangoul H, Gale RP, Hale GA, Horan J, Isola L, Maziarz RT, van Rood JJ, Gupta V, Halter J, Reddy V, Tiberghien P, Litzow M, **Anasetti C**, Pavletic S, Ringden O. Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigen-Identical Sibling Transplants for Adults With Leukemia. *J. Clin. Oncol.* 26:5728-34, 2008. PMC2645611
  177. Guo F, Iclozan C, Suh WK, **Anasetti C**, and Yu XZ. CD28 controls differentiation of regulatory T cells from naive CD4 T cells. *J Immunol* 181:2285-91, 2008. PMC2688779
  178. Davies SM, Wang D, Wang T, Arora M, Ringde O, **Anasetti C**, Pavletic S, Casper J., Macmillan M., Sanders J, Wall D, Kernan NA. Recent decrease in acute graft vs host disease in children with leukemia receiving unrelated donor marrow transplants. *Biol. Blood Marrow Transplant.* 15:360-6, 2009
  179. Ringden O, Pavletic, SZ, **Anasetti C**, Barrett AJ, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C, Cairo MS, Gale RP, Gupta V, Hahn T, Hale GA, Halter J, Jagasia M, Litzow MR, Locatelli F, Marks DI, McCarthy PL, Cowan MJ, Petersdorf EW, Russell JA, Schiller GJ, , Schouten H, Spellman S, Verdonck LF, Wingard JR, Horowitz MM and Arora M. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. *Blood* 113:3110-8, 2009. PMC2662650
  180. Carnevale-Schianca F, Leisenring W, Martin PJ, Furlong T, Schoch G, **Anasetti C**, Appelbaum FR, Carpenter PA, Deeg HJ, Kiem HP, Storb R, McDonald GB and Nash RA. Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study. *Biol. Blood Marrow Transplant* 15:749-56, 2009. PMC2684865
  181. Pidala J, Kim J and **Anasetti C**. Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. *Biol. Blood Marrow Transplant* 15:881-5, 2009.
  182. Yu Y, Iclozan C, Yamazaki T, Yang X, **Anasetti C**, Dong C, and Yu XZ. Abundant c-Fas-associated death domain-like interleukin-1converting enzyme inhibitory protein expression determines resistance of T helper 17 cells to activation-induced cell death. *Blood* 114:1026-8, 2009. PMC2721783
  183. Gergis U, Markey K, Greene J, Kharfan-Dabaja M, Field T, Wetzstein G, Schell MJ, Huang Y, **Anasetti C** and Perkins J. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. *Bone Marrow Transplant* 45:662-7, 2010. PMC2850960
  184. Salinger DH, Blough DK, Vicini P, **Anasetti C**, O'Donnell PV, Sandmaier BM, McCune JS. A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients. *Clin. Cancer Res* 15:5280-7, 2009. PMID: PMC2763506.
  185. Pidala J, Kim J Field T, McBride A, Kharfan-Dabaja M, Perkins J, Fernandez H, Perez L, Ayala E and **Anasetti C**. Infliximab for managing steroid-refractory acute graft-versus-host disease. *Biol. Blood Marrow Transplant* 15:1116-21, 2009.
  186. Pidala J, Kim J, Perkins J, Field T, Fernandez H, Perez L, Ayala E, Kharfan-Dabaja M, and **Anasetti C**. Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. *Bone Marrow Transplant* 45:919-24, 2010.
  187. Iclozan C, Yu Y, Liu C, Liang Y, Yi T, **Anasetti C**, and Yu XZ. T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. *Biol Blood Marrow Transplant* 16:170-8, 2010.
  188. Hoda D, Pidala J, Salgado-Vila N, Kim J, Perkins J, Bookout R, Field T, Perez L, Ayala E, Ochoa-Bayona JL, Raychaudhuri J, Alsina M, Greene J, Janssen W, Fernandez HF, **Anasetti C**, Kharfan-Dabaja MA. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. *Bone Marrow Transplant* 45:1347-51, 2010.
  189. Pidala J, **Anasetti C**, Kharfan-Dabaja MA, Cutler C, Sheldon A, and Djulbegovic B. Decision analysis of

- peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. *Biol. Blood Marrow Transplant* 15:1415-21, 2009.
190. Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E, Perez L, Xu M, Alsina M, Ochoa L, Sullivan D, Janssen W, and **Anasetti C**. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. *Biol. Blood Marrow Transplant* 16:937-47, 2010.
  191. Spellman S, Bray R, Rosen-Bronson S, Haagenson M, Klein J, Flesch S, Vierra-Green C, and **Anasetti C**. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. *Blood* 115:2704-8, 2010.
  192. Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, Fernandez HF, Janssen W, Lancet J, Perez L, Sullivan D, List A, and **Anasetti C**. 5-Azacytidine for myelodysplasia before allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant* 45:255-60, 2010.
  193. Perez L, Parquet N, Meads M, **Anasetti C**, and Dalton W. Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. *Eur. J. Haematol* 84:212-22, 2010.
  194. Uberti JP, Agovi MA, Tarima S, Haagenson M, Gandham S, **Anasetti C**, Baker KS, Bolwell BJ, Bornhauser M, Chan KW, Copelan E, Davies SM, Finke J, Hale GA, Kollman C, McCarthy PL, Ratanatharathorn V, Ringdén O, Weisdorf DJ, Rizzo JD. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia. *Bone Marrow Transplant* 46:34-43, 2011.
  195. Pidala J, Kim J, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez H, **Anasetti C**. Dysglycemia following glucocorticoid therapy for acute graft vs. host disease adversely affects transplantation outcomes. *Biol. Blood Marrow Transplant* 17:239-48, 2011.
  196. Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancet J, Brand L, Field T, Ayala E, Janssen W, List AF, **Anasetti C**. Severe hypoalbuminemia at day 90 predicts worse non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. *Biol. Blood Marrow Transplant* 17:384-93, 2011..
  197. Pidala J, Kim J, **Anasetti C**, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L and Fernandez H. Pharmacokinetic targeting of intravenous Busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. *J Hematol Oncol*, *J Hematol Oncol*. 3:36, 2010. PMC2958877.
  198. Nishihori T, Perkins J, Kim J, Field T, Pidala J, Roman-Diaz J, Komrokji RS, Fernandez HF, **Anasetti C**, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution. *Am J Hematol* 85:904-7, 2010.
  199. Pidala J, Kim J, Roman-Diaz J, Shapiro J, Nishihori T, Bookout R, **Anasetti C**, Kharfan-Dabaja MA. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. *Ann Transplant* 15:21-9, 2010
  200. Semple K, Yu Y, Wang D, **Anasetti C**, Yu XZ. Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice. *Biol Blood Marrow Transplant*. 17:309-18, 2011. PMC3039088.
  201. Semple K, Nguyen A, Yu Y, Wang H, **Anasetti C**, Yu XZ. Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through Lck signaling. *Blood* 117:3096-103, 2011. PMC3062312.
  202. Pidala J, Roman-Diaz J, Kim J, Nishihori T, Perkins J, Tate C, Ochoa-Bayona JL, Field T, Fernandez HF, Tomblyn M, Ayala E, **Anasetti C**, Kharfan-Dabaja MA. Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. *Int J Hematol* 93:206-12, 2011.
  203. Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Ayala E, Perez L, Fernandez H, Fancher K, Tate C, Shaw LM, Milone MC, Gardiner J, Miller S, and **Anasetti C**. Pharmacokinetic Targeting of Intravenous Busulfan with Fludarabine (FluBu) as Conditioning Prior to Hematopoietic Cell Transplant: The Effect of First Dose Area Under the Concentration Time Curve (AUC) on Transplant-Related Outcomes. *Bone Marrow Transplant* 46:1418-25, 2011.
  204. Pidala J, Kim J, **Anasetti C**, Kharfan-Dabaja MA, Field T, Perkins J, Ayala E, Perez L, and Fernandez H. Targeted Intravenous Busulfan and Fludarabine (t-IV Bu/Flu) provides effective control of Acute Myelogenous Leukemia in adults with reduced toxicity. *Bone Marrow Transplantation*. *Bone Marrow*

- Transplant 46:641-9, 2011.
205. Woolfrey A, Klein JP, Haagenson M, Spellman S, Petersdorf E, Oudshoorn M, Gajewski J, Hale GA, Horan J, Battiwalla M, Marino SR, Setterholm M, Ringden O, Hurley C, Flomenberg N, **Anasetti C**, Fernandez-Vina M, Lee SJ. HLA-C Antigen Mismatch Is Associated with Worse Outcome in Unrelated Donor Peripheral Blood Stem Cell Transplantation. *Biol Blood Marrow Transplant* 17:885-92 2011. PMC3071866.
  206. Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Ayala E, Perez L, Fernandez H, Fancher K, Tate C, Shaw LM, Milone MC, Gardiner JA, Miller S, **Anasetti C**. Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. *Bone Marrow Transplant* 46:1418-25, 2011.
  207. Pidala J, Tomblyn M, Nishihori T, Ayala E, Field T, Fernandez H, Perez L, Locke F, Alsina M, Ochoa JL, Perkins J, Tate C, Shapiro J, Conwell M, Bookout R, **Anasetti C**. ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 17:1237-44, 2011
  208. Santarone S, Pidala J, Di Nicola M, Field T, Alsina M, Ayala E, Janssen W, Kharfan-Dabaja MA, Ochoa L, Perez L, Perkins J, Raychaudhuri J, Fernandez H, **Anasetti C**. Fludarabine and Pharmacokinetic-Targeted Busulfan Before Allografting for Adults with Acute Lymphoid Leukemia. *Biol Blood Marrow Transplant* 17:1505-11, 2011.
  209. Semple K, Nguyen A, Yu Y, Wang H, **Anasetti C**, Yu XZ. Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through Lck signaling. Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through Lck signaling. *Blood*. 117:3096-103, 2011. PMC3062312
  210. Pidala J, Roman-Diaz J, Kim J, Nishihori T, Perkins J, Tate C, Ochoa-Bayona JL, Field T, Fernandez HF, Tomblyn M, Ayala E, **Anasetti C**, Kharfan-Dabaja MA. Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. *Int J Hematol*. 93:206-12, 2011.
  211. Pidala J, Lee SJ, Quinn G, Jim H, Kim J, **Anasetti C**. Variation in management of immune suppression after allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant* 17:1528-36, 2011.
  212. Pidala J, Tomblyn M, Nishihori T, Field T, Ayala E, Perkins J, Fernandez H, Locke F, Perez L, Ochoa JL, Alsina M, **Anasetti C**. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. *Haematologica*. 96;1351-6, 2011. PMC3166106.
  213. Pidala J, Kim J, **Anasetti C**, Nishihori T, Betts B, Field T, Perkins J. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. *Haematologica* 96:1678-84, 2011. PMC3208686.
  214. Yu Y, Wang D, Liu C, Kaosaard K, Semple K, **Anasetti C**, Yu XZ. Prevention of GVHD while sparing GVL by targeting Th1 and Th17 transcription factor T-bet and ROR $\gamma$ t in mice. *Blood* 118:5011-20, 2011. PMC3208306
  215. Pidala J, Perez L, Beato F, **Anasetti C**. Ustekinumab demonstrates activity in glucocorticoid-refractory acute GVHD. *Bone Marrow Transplant*. 47:747-8, 2012.
  216. Veerapathran A, Pidala J, Beato F, Yu XZ, **Anasetti C**. Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. *Blood* 118:5671-80, 2011.
  217. Pidala J, Djulbegovic B, **Anasetti C**, Kharfan-Dabaja M, Kumar A. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. *Cochrane Database Syst Rev* CD008818, 2011.
  218. Eapen M, Klein JP, Sanz GF, Spellman S, Ruggeri A, **Anasetti C**, Brown M, Champlin RE, Garcia-Lopez J, Hattersely G, Koegler G, Laughlin MJ, Michel G, Nabhan SK, Smith FO, Horowitz MM, Gluckman E, Rocha V; for the Eurocord-European Group for Blood and Marrow Transplantation, Netcord, and the Center for International Blood and Marrow Transplant Research. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. *Lancet Oncol* 12:1214-1221, 2011. PMC3245836.
  219. Weisdorf D, Cooley S, Devine S, Fehninger T, Dipersio J, **Anasetti C**, Waller E, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J. T-Cell Depleted Partial Matched Unrelated Donor Transplant for Advanced Myeloid Malignancy: KIR Ligand Mismatch and Outcome. *Biol Blood*

- Marrow Transplant. 18:937-43, 2012. PMC3319849.
220. Perkins JB, Kim J, **Anasetti C**, Fernandez HF, Perez LE, Ayala E, Kharfan-Dabaja MA, Tomblyn MR, Sullivan DM, Pidala JA, Field TL. Maximally Tolerated Busulfan Systemic Exposure in Combination with Fludarabine as Conditioning before Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant.* 18:1099-107, 2012.
  221. Yu Y, Yu J, Iclozan C, Kaosaard K, **Anasetti C**, Yu XZ. Bim is required for T-cell allogeneic responses and graft-versus-host disease in vivo. *Am J Blood Res.* 2:77-85, 2012. PMC3301434.
  222. Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, **Anasetti C**, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. *Br J Haematol.* 157:553-63, 2012.
  223. Janssen WE, Rahn D, Hackett M, Coyle D, Tomblyn M, Smilee RC, **Anasetti C**, Fernandez HF. Apheresis and transplant of hematopoietic progenitor cells (HPC) from allogeneic donors of age above 60 years. *Bone Marrow Transplant.* 47:1520-5, 2012.
  224. Perkins JB, Shapiro JF, Bookout RN, Yee GC, **Anasetti C**, Janssen WE, Fernandez HF. Retrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: Clinical and economic outcomes. *Am J Hematol.* 87:673-7, 2012.
  225. Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez H, Tomblyn M, Perez L, Perkins J, Xu M, Janssen W, Veerapathran A, Betts B, Locke FL, Ayala E, Field T, Ochoa-Bayona L, Alsina M, **Anasetti C**. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. *Haematologica* 97:1882-9, 2012.
  226. Wang D, Iclozan C, Liu C, Xia C, **Anasetti C**, Yu XZ. LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice. *Biol Blood Marrow Transplant.* 18:1182-1190, 2012. PMC3417119.
  227. Pidala J, Craig B, Lee SJ, Majhail N, Quinn G, **Anasetti C**. Practice variation in physician referral for allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant.*48:63-7, 2013, PMC3549547.
  228. Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez HF, Field T, Locke FL, Nishihori T, Ochoa JL, Perez L, Perkins J, Shapiro J, Tate C, Tomblyn M, **Anasetti C**. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. *Bone Marrow Transplant.* 2012 Aug 6. PMID: 22863723.
  229. Boucher K, Parquet N, Widen R, Shain KH, Baz R, Alsina M, Koomen J, **Anasetti C**, Dalton WS, Perez L. Stemness of B cell progenitors in multiple myeloma bone marrow. *Clin Cancer Res.* 18:6155-68, 2012.
  230. **Anasetti C**, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL. Peripheral-blood stem cells versus bone marrow from unrelated donors. *Blood and Marrow Transplant Clinical Trials Network.* *N Engl J Med.* 367:1487-96, 2012.
  231. Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, **Anasetti C**, Weisdorf D, Miller JS. Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen. *J Immunol.*189:5082-8, 2012. ; PMC3490031.
  232. Yu Y, Cho HI, Wang D, Kaosaard K, Anasetti C, Celis E, Yu XZ. Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms. *J Immunol.* 2013 Feb 15;190:1873-81. PMC3563723.
  233. Wang D, Yu Y, Haarberg K, Fu J, Kaosaard K, Nagaraj S, **Anasetti C**, Gabrilovich D, Yu XZ. Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice. *Biol Blood Marrow Transplant.* 2013 Jan 30. PMID: 23376089.
  234. Nishihori T, Ochoa-Bayona JL, Kim J, Pidala J, Shain K, Baz R, Sullivan D, Jim HS, **Anasetti C**, Alsina M. Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma. *Bone Marrow Transplant.* 2013 Apr 1. PMID: 23542223.
  235. Fernández-Viña MA, Klein JP, Haagenson M, Spellman SR, **Anasetti C**, Noreen H, Baxter-Lowe LA, Cano P, Flomenberg N, Confer DL, Horowitz MM, Oudshoorn M, Petersdorf EW, Setterholm M, Champlin R, Lee SJ, de Lima M. Multiple mismatches at the low expression HLA loci DP, DQ,

- DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. *Blood*. 2013 Apr 17. PMID: 23596045
236. Kharfan-Dabaja MA, **Anasetti C**, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Phase II study of CD4+guided pentostatin lymphodepletion and pharmacokinetically-targeted busulfan as conditioning for hematopoietic cell allografting. *Biol Blood Marrow Transplant*. 2013 Apr 27. PMID: 23632090
237. Yu Y, Wang D, Kaosaard K, Liu C, Fu J, Haarberg K, **Anasetti C**, Beg AA, Yu XZ. c-Rel is an essential transcription factor for the development of acute graft-versus-host disease in mice. *Eur J Immunol*. 2013 May 29. PMID: 23716202.
238. Haarberg KM, Li J, Heinrichs J, Wang D, Liu C, Bronk CC, Kaosaard K, Owyang AM, Holland S, Masuda E, Tso K, Blazar BR, **Anasetti C**, Beg AA, Yu XZ. Pharmacologic inhibition of PKC $\alpha$  and PKC $\theta$  prevents GVHD while preserving GVL activity in mice. *Blood*. 2013 Aug 1. PMID 23908466.
239. Veerapathran A, Pidala J, Beato F, Betts B, Kim J, Turner JG, Hellerstein MK, Yu XZ, Janssen W, **Anasetti C**. Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease. PMID: 23908471.
240. Pidala J, Wang T, Haagenson M, Spellman SR, Askar M, Battiwalla M, Baxter-Lowe LA, Bitan M, Fernandez-Viña M, Gandhi M, Jakubowski AA, Maiers M, Marino SR, Marsh SG, Oudshoorn M, Palmer J, Prasad VK, Reddy V, Ringden O, Saber W, Santarone S, Schultz KR, Setterholm M, Trachtenberg E, Turner EV, Woolfrey AE, Lee SJ, **Anasetti C**. Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. *Blood*. 2013 Aug 27. PMID: 23982174.
241. Kunter G, Perkins JB, Pidala J, Nishihori T, Kharfan-Dabaja MA, Field T, Fernandez H, Perez L, Locke F, Ayala E, Tomblyn M, Ochoa-Bayona JL, Betts B, Nieder M, **Anasetti C**. Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. *Bone Marrow Transplant*. 2013 Sep 2. PMID: 23995098.
242. Betts BC, Veerapathran A, Pidala J, Yu XZ, **Anasetti C**. T5 polarization promotes iTregs and suppresses human T-cell alloresponses while preserving CTL capacity. *J Leukoc Biol*. 2013 Sep 25. PMID: 24068731.
243. Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, **Anasetti C**, Arcese W, Barker JN, Baxter-Lowe LA, Brown M, Fernandez-Vina MA, Freeman J, He W, Paolo Iori A, Horowitz MM, Locatelli F, Marino S, Maiers M, Michel G, Sanz GF, Gluckman E, Rocha V. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. *Blood*. 2013 Oct 18. PMID: 24141369.
244. Switzer GE, Bruce JG, Harrington D, Haagenson M, Drexler R, Foley A, Confer D, Bishop M, Anderlini P, Rowley S, Leitman SF, **Anasetti C**, Wingard JR. Health-related QoL of Bone Marrow versus PBSC Donors: A Pre-specified Subgroup Analysis from a Phase III RCT-BMTCTN protocol 0201. *Biol Blood Marrow Transplant*. 2013 Oct 31. PMID: 24184336

### **Book Chapters**

1. Sullivan, K.M., Witherspoon, R., Deeg, H.J., Doney, K., Appelbaum, F., Sanders, J., Lum, L., Loughran, T., Hill, R., **Anasetti, C.**, Shields, A., Nims, J., Shulman, H., Storb, R., Thomas, E.D.: Chronic graft-versus-host disease in man. In: Progress in Bone Marrow Transplantation, UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 53, Gale, R.P. and Champlin, R. (eds.). New York: Alan R. Liss, Inc. 473-487, 1987.
2. Hansen, J.A., Beatty, P.G., **Anasetti, C.**, Clift, R.A., Martin, P.J., Sanders, J., Sullivan, K., Buckner, C.D., Storb, R., Thomas, E.D.: Treatment of leukemia by marrow transplantation from donors other than HLA genotypically identical siblings. In: Progress in Bone Marrow Transplantation, UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 53, Gale, R.P. and Champlin, R. (eds.). New York, N.Y. Alan R. Liss, Inc. 667-675, 1987.
3. Braun, M., **Anasetti, C.**, Martin, P.J., Hansen, J.A.: The E-rosette receptor in human lymphocytes. In: Immunochemical Techniques, Methods in Enzymology Series, Volume 150, New York: Academic Press, Inc. 536-547, 1987.
4. **Anasetti, C.**, Martin, P.J., Morishita, Y., Ledbetter, J.A., Hansen, J.A.: Enhancement of cytolytic activity by bridging the CD2 sheep erythrocyte binding protein and the CD16 Fc-receptor. In: Leukocyte Typing III, McMichael, A.J. (ed.). Oxford: Oxford University Press,

5. Storb, R., Doney, K., Thomas, E.D., **Anasetti, C.**, Appelbaum, F., Beatty, P., Bensinger, W., Buckner, C.D., Cliff, R., Fefer, A., Hansen, J., Hill, R., Martin, P., McGuffin, R., Sanders, J., Singer, J., Stewart, P., Sullivan, K., Witherspoon, R.: Allogeneic and syngeneic marrow transplantation for aplastic anemia: Overview of Seattle results. In: Recent Advances and Future Directions in Bone Marrow Transplantation, (Experimental Hematology Today--1987), Baum, S.J., Santos, G.W., and Takaku, F. (eds.). New York: Springer-Verlag, 119-124, 1988.
6. Hansen, J.A., **Anasetti, C.**, Beatty, P.G., Martin, P.J., Amos, D., Thomas, E.D.: Marrow transplants from HLA haploidentical donors: Failure to engraft and late graft failure. In: T-Cell Depletion in Allogeneic Bone-Marrow Transplantation. Serono Symposia Review No. 13, Martelli, M.F., Grignani, F., and Reisner, Y. (eds.). New York: Raven Press, 111-121, 1988.
7. **Anasetti, C.**, Amos, D., Beatty, P.G., Martin, P.J., Thomas, E.D., Hansen, J.A.: Risk factors for graft rejection of marrow transplants from HLA-haploidentical donors. In: Immunobiology of HLA: Immunogenetics and Histocompatibility, Volume II, Dupont, B. (ed.). New York: Springer-Verlag, 516-517, 1989.
8. Sullivan, K.M., Witherspoon, R.P., Storb, R., **Anasetti, C.**, Appelbaum, F.R., Bigelow, C., Clark, J., Doney, K., Hill, R., Loughran, T., Matthews, D.D., Nims, J., Petersen, F., Sanders, J., Schüning, F., Shields, A., Strom, S., Thomas, E.D.: Chronic graft-versus-host disease: Recent advances in diagnosis and treatment. In: Bone Marrow Transplantation: Current Controversies. UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 91, Gale, R.P. and Champlin, R. (eds.). New York: Alan R. Liss, Inc. 511-522, 1989.
9. Storb, R., Deeg, H.J., **Anasetti, C.**, Appelbaum, F., Beatty, P., Doney, K., Hansen, J., Schuening, F., Simmons, P., Sullivan, K., Witherspoon, R., Thomas, E.D., Torok-Storb, B.: Pathophysiology of marrow graft failure: A review of the Seattle data. In: Bone Marrow Transplantation: Current Controversies, UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 91, Gale, R.P. and Champlin, R. (eds.). New York: Alan R. Liss, Inc. 19-30, 1989.
10. Buckner, C.D., Sanders, J.E., **Anasetti, C.**, Beatty, P., Hansen, J.A., Storb, R., Cliff, R.A., Thomas, E.D.: Donors other than HLA-identical siblings. In: Advances and Controversies in Thalassemia Therapy: Bone Marrow Transplantation and Other Approaches, Buckner, C.D., Gale, R.P., and Lucarelli, G. (eds.). New York: Alan R. Liss, Inc. 383-390, 1989.
11. Sanders, J.E., Buckner, C.D., Sullivan, K.M., Doney, K., Appelbaum, F., Witherspoon, R., **Anasetti, C.**, Storb, R., Thomas, E.D.: Growth and development after bone marrow transplantation. In: Advances and Controversies in Thalassemia Therapy: Bone Marrow Transplantation and Other Approaches, Buckner, C.D., Gale, R.P., and Lucarelli, G. (eds.). New York: Alan R. Liss, Inc. 375-382, 1989.
12. Sullivan, K.M., Buckner, C.D., Sanders, J.E., **Anasetti, C.**, Appelbaum, F.R., Clark, J., Doney, K., Meyers, J., Sale, G., Storb, R., Thomas, E.D., Witherspoon, R.P.: Long-term complications of bone marrow transplantation. In: Advances and Controversies in Thalassemia Therapy: Bone Marrow Transplantation and Other Approaches, Buckner, C.D., Gale, R.P., and Lucarelli, G. (eds.). New York: Alan R. Liss, Inc. 367-374, 1989.
13. Beatty, P.G., **Anasetti, C.**, Thomas, E.D., Hansen, J.A.: Marrow transplantation from relatives other than HLA-identical siblings. In: Bone Marrow Transplantation: Current Controversies, UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 91, Gale, R.P. and Champlin, R. (eds.). New York, NY: Alan R. Liss, Inc. 619-624, 1989.
14. Hansen, J.A., **Anasetti, C.**, Beatty, P.G., Martin, P.J., Thomas, E.D.: Allogeneic marrow transplantation. The Seattle experience. In: Clinical Transplants, Terasaki, P. (ed.). 105-114, 1989.
15. Storb, R., Buckner, C.D., Cliff, R.A., Appelbaum, F.R., Doney, K.C., Martin, P., **Anasetti, C.**, Hansen, J., Sanders, J.E., Petersen, F.B., Sullivan, K.M., Witherspoon, R.P., Thomas, E.D.: Marrow grafting for acute leukemia: Results and future treatment strategies. In: Haematology and Blood Transfusion, Acute Leukemias II, Volume 33, Büchner, T., Schellong, G., Hiddemann, W., and Ritter, J. (eds.). Berlin, Heidelberg: Springer-Verlag, 629-635, 1990.
16. Doney, K., Kopecky, K., Storb, R., Buckner, C.D., Singer, J., **Anasetti, C.**, Appelbaum, F., Beatty, P., Bensinger, W., Berenson, R., Cliff, R., Deeg, H.J., Hansen, J., Hill, R., Loughran, T., Martin, P., Petersen, F.B., Sale, G., Sanders, J., Sullivan, K., Stewart, P., Weiden, P., Witherspoon, R., Thomas, E.D.: Long-term comparison of immunosuppressive therapy with antithymocyte globulin to bone marrow transplantation in aplastic anemia. In: Aplastic Anemia and Other Bone Marrow Failure Syndromes, Shahidi, N.T. (ed.). New York: Springer-Verlag, Chapter 9: 104-114, 1990.
17. **Anasetti, C.**, Beatty, P.G.: Selection of marrow donors for patients lacking an HLA identical sibling. In:

- Bone Marrow Transplantation, Champlin, R.(ed.).Boston: Kluwer Academic Publishers, 129-140, 1990.
18. Beatty, P.G., **Anasetti, C.**: Marrow transplantation from donors other than HLA identical siblings. In: Bone Marrow Transplantation, Vol 4, Gale, R. (ed.). Boston: Blackwell, Chapter 26: 677-686, 1990.
  19. Sullivan, K.M., Weiden, P.L., Fefer, A., Appelbaum, F.R., **Anasetti, C.**, Buckner, C.D., Clift, R., Doney, K., Fisher, L., Martin, P., Petersen, F., Sanders, J., Singer, J., Stewart, P., Witherspoon, R.P., Hansen, J.A., Thomas, E.D., Storb, R.: Graft-versus-leukemia effect of allogeneic bone marrow transplantation in patients with acute nonlymphocytic leukemia. In: Acute Myelogenous Leukemia: Progress and Controversies, Gale, R.P. (ed.). New York, NY: Wiley-Liss, Inc. 391-401, 1990.
  20. Storb, R., **Anasetti, C.**, Appelbaum, F., Beatty, P., Bensinger, W., Buckner, C.D., Clift, R., Doney, K., Hansen, J., Loughran, T., Martin, P., Pepe, M., Petersen, F., Sanders, J., Singer, J., Stewart, P., Sullivan, K., Witherspoon, R., Thomas, E.D.: Allogeneic marrow transplantation for aplastic anemia: Major issues. In: New Strategies in Bone Marrow Transplantation, UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 137, Champlin, R.E. and Gale, R.P. (eds.). New York: Wiley-Liss, Inc. 73-85, 1991.
  21. Storb, R., Appelbaum, F., Badger, C., Bernstein, I., Buckner, C.D., Petersen, F.B., Martin, P., Hansen, J., **Anasetti, C.**, Sandmaier, B., Bianco, J., Schuening, F., Thomas, E.D.: Conditioning regimens in bone marrow transplantation. In: Organ Transplantation 1990, Abouna, G.M., Kumar, M.S.A., and White, A.G. (eds.). Dordrecht, The Netherlands: Kluwer Academic Publishers, 437-442, 1991.
  22. Hansen, J.A., Mickelson, E.M., Choo, S.Y., Petersdorf, E.W., **Anasetti, C.**, Martin, P.J., Thomas, E.D.: Clinical bone marrow transplantation: Donor selection and recipient monitoring. In: Manual of Clinical Laboratory Immunology, 4th Edition, Rose, N.R., De Macario, E.C., Fahey, J.L., Friedman, H., and Penn, G.M. (eds.). Washington: American Society for Microbiology, Chapter 129: 850-866, 1992.
  23. Hansen, J.A., **Anasetti, C.**, Petersdorf, E.W., Choo, S.Y., Mickelson, E.M., Martin, P.J.: The status of clinical marrow transplantation and current issues in donor matching. In: HLA 1991, Volume 1, Proceedings of the Eleventh International Histocompatibility Workshop and Conference Held in Yokohama, Japan. Tsuji, K., Aizawa, M., and Sasazuki, T. (eds.). Oxford: Oxford University Press, 13-19, 1992.
  24. McGlave, P.B., Antman, K., **Anasetti, C.**: New developments in bone marrow transplantation. In: Hematology 1992, Menitove, J.E. and McArthur, J.R. (eds.). Anaheim,CA: American Society of Hematology, 96-107, 1992.
  25. **Anasetti, C.**, The Seattle Marrow Transplant Team: Marrow transplants from unrelated volunteer donors for treatment of acute leukemia. In: Progressi in Ematologia Clinica, Volume 12, Bernasconi, C. (ed.). Italy: Edizioni Medico Scientifiche Pavia, Chapter 21: 243-248, 1993.
  26. Hansen, J.A., **Anasetti, C.**, Martin, P.J., Mickelson, E.M., Petersdorf, E., Thomas, E.D.: Allogeneic marrow transplantation: the Seattle experience. In: Clinical Transplants 1993, Terasaki, P. and Cecka, J.M. (eds.). Los Angeles: UCLA Tissue Typing Laboratory, Chapter 18: 193-210, 1993.
  27. **Anasetti, C.**, Hansen, J.A.: Bone marrow transplantation from HLA-partially matched related donors and unrelated volunteer donors. In: Bone Marrow Transplantation, Forman, S.J., Blume, K.G., and Thomas, E.D. (eds.). Boston, MA: Blackwell Scientific Publications, Chapter 51: 665-680, 1994.
  28. **Anasetti, C.**, Petersdorf, E.W., Martin, P.J., Hansen, J.A.: Marrow transplantation from unrelated volunteer donors. In: Technical and Biological Components of Marrow Transplantation, Buckner, C.D. and Clift, R. (eds.). Boston: Kluwer Academic Publishers, Chapter 6: 137-168, 1995.
  29. Deeg, H.J., Doney, K., **Anasetti, C.**, Storb, R.: Transplant and nontransplant therapy for patients with severe aplastic anemia: an update of the Seattle experience. In: Ontogeny of hematopoiesis Aplastic anemia, Gluckman, E. and Coulombel, L.(eds.). Montrouge, France:John Libbey Eurotext, 307-312, 1995.
  30. **Anasetti, C.**: Marrow transplantation from unrelated volunteer donors. In: Haematology 1996, Education Programme of the 26th Congress of the International Society of Haematology at Singapore, August 25-29, 1996, McArthur, J.R., Lee, S.H., Wong, J.E.L., and Ong, Y.W. (eds.). Seattle: I.S.H. Education Book, 21-26, 1996.
  31. Chalupny, N.J., Zhu, L., Yu, X.-Z., **Anasetti, C.**: Cell cycle control of T cell apoptosis induced by activation through the T cell antigen receptor. In: Mechanisms of Lymphocyte Activation and Immune Regulation VI: Cell Cycle and Programmed Cell Death in the Immune System, Volume 406, Advances in Experimental Medicine and Biology. Gupta, S. and Cohen, J.J. (eds.). New York: Plenum Press, Chapter 6: 57-67, 1996.
  32. Hansen, J.A., Mickelson, E., Petersdorf, E.W., Anderson, J., Sierra, J., Martin, P.J., **Anasetti, C.**:



- Marrow transplants from unrelated donors. In: Clinical Transplants 1995, Cecka and Terasaki (ed.). Los Angeles: Tissue Typing Laboratory, Chapter 24: 279-289, 1996.
33. Hansen, J.A., Sierra, J., Petersdorf, E.W., Martin, P.J., **Anasetti, C.**: Hematopoietic stem cell transplants from unrelated donors. In: Bone Marrow Transplantation. Basic and Clinical Studies, Ikehara, S., Takaku, F., and Good, R.A. (eds.). Tokyo: Springer-Verlag, 233-245, 1996.
  34. Hakimi, J., Mould, D., Waldmann, T.A., Queen, C., **Anasetti, C.**, Light, S.: Development of Zenapax™: a humanized anti-Tac antibody. In: Antibody Therapeutics, Taub, R. (ed.). Boca Raton: CRC Press, Inc. Chapter 12: 277-299, 1997.
  35. Clift, R.A., **Anasetti, C.**: Allografting for chronic myeloid leukemia. In: Clinical Haematology, Volume 10 No. 2, Chronic Myeloid Leukaemia. Goldman, J.M. (ed.). London: W.B. Saunders, Chapter 9: 319-336, 1997.
  36. Hansen, J.A., Radich, J.P., Petersdorf, E., Martin, P.J., **Anasetti, C.**: Retransplantation of marrow and hematopoietic stem cells from normal donors. In: Retransplantation, Proceedings of the 29th Conference on Transplantation and Clinical Immunology, 9-11 June, 1997. Touraine, J.L., Traeger, J., Bétuel, H., Dubernard, J.M., Revillard, J.P., and Dupuy, C. (eds.). Netherlands: Kluwer Academic Publishers, Chapter 3: 17-23, 1997.
  37. Petersdorf, E.W., Longton, G.M., **Anasetti, C.**, Martin, P.J., Mickelson, E.M., Smith, A.G., Hansen, J.A. Marrow transplantation from unrelated donors: The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. In: Year Book of Hematology® 1997, Spivak, J.L., Blume, K.G., Bell, W.R., Ness, P.M., Quesenberry, P.J., and Wiernik, P.H. (eds.). St. Louis, MO: Mosby, Chapter 5-14: 349-351, 1997.
  38. Hansen, J.A., Petersdorf, E.W., Pei, J., Mickelson, E., Martin, P.J., **Anasetti, C.** Transplantation of hematopoietic stem cells from HLA matched unrelated donors. In: HLA: Genetic Diversity of HLA: Functional and Medical Implications, Volume II, Charron, D. (ed.). Paris: EDK Medical and Scientific International Publisher, 84-90, 1997.
  39. Petersdorf, E., **Anasetti, C.**, Servida, P., Martin, P., Hansen, J.: Effect of HLA matching on outcome of related and unrelated donor transplantation therapy for chronic myelogenous leukemia. Biology and Therapy of Chronic Myelogenous Leukemia 12: 107-121, 1998.
  40. **Anasetti, C.**, Petersdorf, E.W., Martin, P.J., Hansen, J.A.: Marrow transplantation from unrelated volunteer donors. In: Il Trapianto di Cellule Staminali Allogeneiche in Ematologia, Volume 6, Morra, E. (ed.). Milano, Italy: Associazione Malattie del Sangue, Chapter 7: 73-82, 1998.
  41. Sierra J, Bjerke JW, Hansen JA, Martin PJ, Petersdorf EW, **Anasetti C**: Marrow transplants from unrelated donors for the treatment of high-risk acute leukemia. In: Acute Leukemias VII- Experimental Approaches and Novel Therapies, Hiddemann W, Büchner T, Wörmann B, Ritter J, Creutzig U, Keating M, Plunkett W (eds). Springer-Verlag, Germany, pp 1111-1124, 1998.
  42. Mickelson, E.M., Petersdorf, E., **Anasetti, C.**, Martin, P., Hansen, J.A.: HLA matching in hematopoietic cell transplantation. In: HLA 1998, Gjertson, D.W. and Terasaki, P.I. (eds.). Lenexa, Kansas: American Society for Histocompatibility and Immunogenetics, Chapter 3: 47-56, 1998.
  43. **Anasetti, C.**: Hematopoietic cell transplantation from HLA partially matched related donors. In: Hematopoietic Cell Transplantation, 2nd Edition, Thomas, E.D., Blume, K.G., and Forman, S.J. (eds.). Boston: Blackwell Science, Chapter 77: 904-914, 1999.
  44. Woolfrey, A.E., **Anasetti, C.**, Petersdorf, E.W., Martin, P.J., Sanders, J.E., Hansen, J.A., Unrelated donor marrow transplantation for treatment of childhood hematologic malignancies – effect of HLA disparity and cell dose. In: Advances in Allogeneic Hematopoietic Stem Cell Transplantation, Burt, R.K., Brush, M.M. (eds.) Chicago: Kluwer Academic Publishers, Chapter 2, 25-51, 1999.
  45. Woolfrey, A.E., Petersdorf, E.W., **Anasetti, C.**, Martin, P.J., Deeg, J., Bensinger, W., Sanders, J.E., Hansen, J.A. Matched unrelated marrow transplantation: The true indications. In: Handbook of Bone Marrow Transplantation, Rowe, J.M., Lazarus, H.M., and Carella, A.M. (eds.). London, UK: Martin Dunitz Ltd, Chapter 3: 41-64, 2000.
  46. Petersdorf, E.W., Malkki, M., Mickelson, E.M., **Anasetti, C.**, Martin, P.J., Smith, A., Hansen, J.A. Unrelated allogeneic bone marrow and stem-cell transplants: Unrelated donor transplants. In: American Society of Clinical Oncology 2001 Educational Book, Perry, M.C. (ed.). Alexandria, VA: American Society of Clinical Oncology, 616-621, 2001.
  47. Giralt, S.A., Goldman, J., **Anasetti, C.**, Cervantes, F., Champlin, R., Cross, N., Hochhaus, A., Klein, J.P., Papadopoulos, E., Sobocinski, K., Weisdorf, D., Horowitz, M. Recommendations for assessment and definitions of response and relapse in CML: a report from the chronic leukemia working committee

- of the IBMTR. In: Chronic Myeloid Leukemia: Biology and Treatment, Carella, A.M., Daley, G.Q., Eaves, C.J., Goldman, J.M., and Hehlmann, R. (eds.). London, UK: Martin Dunitz Ltd., Chapter 22: 357-368, 2001.
48. Petersdorf, E.W., **Anasetti, C.**, Martin, P.J., Hansen, J.A. HLA typing in hematopoietic cell transplantation. In: Neoplastic Diseases of the Blood, Fourth Edition, Wiernik, P.H., Goldman, J.M., Dutcher, J.P., and Kyle, R.A. (eds.). Cambridge, UK: Cambridge University Press, Chapter 58: 1085-1095, 2003.
  49. **Anasetti, C.** Unrelated donor hematopoietic stem cell transplantation. In: Clinical Bone Marrow and Blood Stem Cell Transplantation, Third Edition, Atkinson, K., Champlin, R., Ritz, J., Fibbe, W.E., Ljungman, P., and Brenner, M.K. (eds.). Cambridge, UK: Cambridge University Press, Chapter 67: 1029-1053, 2004.
  50. **Anasetti, C.**, Velardi, A. Hematopoietic cell transplantation from HLA partially matched related donors. In: Thomas' Hematopoietic Cell Transplantation, Third Edition, Blume, K.G., Forman, S.J., and Appelbaum, F.R. (eds.). Oxford, UK: Blackwell Publishing Ltd., Chapter 82: 1116-1131, 2004.
  51. Petersdorf, E., **Anasetti, C.** Unrelated donor stem cell transplantation therapy. In: Hematology, Fourth Edition, Hoffman, R., Benz, E.J., Jr., Shattil, S.J., Furie, B., Cohen, H.J., Silberstein, L.E., and McGlave, P. (eds.). Philadelphia, PA: Elsevier Science, Chapter 97: 1739-1750, 2005.
  52. **Anasetti, C.**, Aversa F., Velardi A. Hematopoietic Cell Transplantation from Human Leukocyte Antigen Partially Matched Related Donors. In Thomas' Hematopoietic Cell Transplantation, Fourth edition. Appelbaum F. R., Forman S.J., Negrin R.S. & Blume K.G. (eds). Oxford, UK. Blackwell Publishing Ltd., Chapter 46: 657-674, 2009.
  53. Ayala, E., **Anasetti, C.** Posttransplant Vaccination Strategies. In Hematopoietic Stem Cell Transplantation, A Handbook for Clinicians. Wingard, J.R., Gastineau, D.A., Leather, H. L., Szczepiorkowski Z. M., and Snyder E. L. (eds). Bethesda, MA. Advancing Transfusion and Cellular Therapies, AABB, Chapter 33: 463-72, 2009.
  54. Petersdorf E., **Anasetti, C.** Unrelated donor stem cell transplantation therapy. In: Hematology, Fifth Edition, Hoffman, R., Benz, E.J., Jr., Shattil, S.J., Furie, B., Cohen, H.J., Silberstein, L.E., and McGlave, P. (eds.). Philadelphia, PA: Elsevier Science, Chapter 103: 1619-1631, 2010.
  55. Pidala J., **Anasetti, C.** Advances in Allogeneic Hematopoietic Cell Transplantation: Progress in Transplantation Technology and Disease-Specific Outcomes. In: Advances in Malignant Hematology, Saba, H.I., Mufti, G J., (eds), West Sussex, UK: Blackwell Publishing Ltd., Chapter 23: 369-383, 2011.

### **Letters, Reviews, Proceedings**

1. Brugia, M., **Anasetti, C.**: Attivita' immunosopressiva e linfocitolitica dei corticosteroidi. Ann. Med. Perugia 73: 387-391, 1980.
2. **Anasetti, C.**, Brugia, M.: Elementi di terapia corticosteroidea. Ann. Med. Perugia 71: 392-400, 1980.
3. **Anasetti, C.**, Di Costanzo, F., Grignani, F.: Immunological classification of acute lymphoblastic leukemia. EOS 2: 149-152, 1982.
4. Hansen, J.A., Beatty, P.G., **Anasetti, C.**, Martin, P.J., Mickelson, E., Thomas, E.D.: Transplantation of hematopoietic stem cells (HSC). Br. Med. Bull. 43: 203-216, 1987.
5. Badger, C., **Anasetti, C.**, Davis, J., Bernstein, I.: Treatment of malignancy with unmodified antibody. Pathol. Immunopathol. Res. 6: 419-434, 1987.
6. **Anasetti, C.**, Storb, R., Longton, G., Witherspoon, R., Doney, K., Sullivan, K.M., Thomas, E.D.: Donor buffy coat cell infusion after marrow transplantation for aplastic anemia. (Letter to the Editor). Blood 72: 1099-1100, 1988.
7. Storb, R., **Anasetti, C.**, Appelbaum, F.R., Beatty, P., Deeg, H.J., Doney, K., Martin, P., Sullivan, K., Witherspoon, R., Thomas, E.D., for the Seattle Marrow Transplant Team: Predictive factors and prevention of acute graft-versus-host disease, the Seattle experience. Bone Marrow Transplant 3: 7-10, 1988.
8. Sanders, J., Sullivan, K., Witherspoon, R., Doney, K., **Anasetti, C.**, Beatty, P., Petersen, F.B.: Long term effects and quality of life in children and adults after marrow transplantation. Bone Marrow Transplantation 4: 27-29, 1989.
9. Beatty, P.G., Hansen, J.A., **Anasetti, C.**, Sanders, J., Buckner, C.D., Storb, R., Thomas, E.D.: Marrow transplantation from unrelated HLA-matched volunteer donors. Transplant. Proc. 21: 2993-2994, 1989.
10. Storb, R., Appelbaum, F.R., Badger, C., Bernstein, I., Buckner, C.D., Petersen, F.B., Martin, P.,

- Hansen, J., **Anasetti, C.**, Sandmaier, B., Bianco, J., Schuening, F., Thomas, E.D., for the Seattle Bone Marrow Transplant Team: New conditioning regimens. *Bone Marrow Transplant* 4: 15, 1989.
11. Sullivan, K.M., Shulman, H.M., Storb, R., **Anasetti, C.**, Appelbaum, F.R., Beatty, P., Doney, K., Loughran, T., Sanders, J., Witherspoon, R.P., Thomas, E.D.: New strategies in the management of chronic graft-versus-host disease. *Bone Marrow Transplant* 4: 47, 1989.
  12. **Anasetti, C.**, Beatty, P.G., Hansen, J.A.: Bone marrow transplantation from unrelated donors or from partially HLA matched family members. *New Trends Ther. Leuk. Lymph.* 5: 19-23, 1990.
  13. Storb, R., Appelbaum, F., Buckner, C.D., Clift, R., **Anasetti, C.**, Beatty, P., Bianco, J., Doney, K., Hansen, J., Martin, P., Sanders, J., Sandmaier, B., Schuening, F., Sullivan, K., Witherspoon, R., Thomas, E.D.: HLA-identical marrow transplantation in the leukemias without T-cell depletion. *Bone Marrow Transplant* 6: 80-84, 1990.
  14. Hansen, J.A., **Anasetti, C.**, Beatty, P.G., Martin, P.J., Sanders, J.E., Storb, R., Thomas, E.D.: Treatment of leukemia by marrow transplantation from HLA incompatible donors. Effect of HLA-disparity on GVHD, relapse and survival. *Bone Marrow Transplant* 6: 108-111, 1990.
  15. Storb, R., Sanders, J.E., Pepe, M., **Anasetti, C.**, Appelbaum, F.R., Buckner, C.D., Deeg, H.J., Doney, K., Hansen, J., Martin, P., Stewart, P., Sullivan, K.M., Thomas, E.D., Witherspoon, R.P.: Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts (Letter). *Blood* 78: 1144-1145, 1991.
  16. Storb, R., **Anasetti, C.**, Appelbaum, F., Bensinger, W., Buckner, C.D., Clift, R., Deeg, H.J., Doney, K., Hansen, J., Loughran, T., Martin, P., Pepe, M., Petersen, F., Sanders, J., Singer, J., Stewart, P., Sullivan, K.M., Witherspoon, R., Thomas, E.D.: Marrow transplantation for severe aplastic anemia and thalassemia major. *Semin. Hematol* 28: 235-239, 1991.
  17. **Anasetti, C.**: The role of the immunogenetics laboratory in marrow transplantation. *Arch. Pathol. Lab Med* 115: 288-292, 1991.
  18. Sullivan, K.M., Agura, E., **Anasetti, C.**, Appelbaum, F.R., Badger, C., Bearman, S., Erickson, K., Flowers, M., Hansen, J.A., Loughran, T., Martin, P., Matthews, D., Petersdorf, E., Radich, J., Riddell, S., Rovira, D., Sanders, J., Schuening, F., Siadak, M., Storb, R., Witherspoon, R.P.: Chronic graft-versus-host disease and other late complications of bone marrow transplantation. *Semin. Hematol.* 28: 250-259, 1991.
  19. Buckner, C.D., **Anasetti, C.**, Bianco, J., Nemunaitis, J.: Allogeneic bone marrow transplantation for patients with hematologic malignancies. *Schweiz. Med. Wochenschr.* 43: 91-101, 1991.
  20. Storb, R., Pepe, M., Deeg, H.J., **Anasetti, C.**, Appelbaum, F.R., Bensinger, W., Buckner, C.D., Clift, R.A., Doney, K., Hansen, J., Martin, P., Pettinger, M., Sanders, J.E., Singer, J., Stewart, P., Sullivan, K.M., Thomas, E.D., Witherspoon, R.P.: Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. (Letter to the Editor). *Blood* 80: 560-561, 1992.
  21. Storb, R., Deeg, H.J., Pepe, M., **Anasetti, C.**, Appelbaum, F.R., Bensinger, W., Buckner, C.D., Clift, R.A., Doney, K., Hansen, J., Longton, G., Martin, P., Sanders, J.E., Singer, J., Stewart, P., Sullivan, K.M., Thomas, E.D., Witherspoon, R.P.: Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia (Letter). *Blood* 79: 3091-3092, 1992.
  22. Storb, R., Longton, G., **Anasetti, C.**, Appelbaum, F.R., Beatty, P., Bensinger, W., Crawford, S., Deeg, H.J., Doney, K., Fefer, A., Hansen, J., Loughran, T., Martin, P., Pepe, M., Petersen, F.B., Sanders, J.E., Singer, J., Stewart, P., Sullivan, K.M., Thomas, E.D., Witherspoon, R.P.: Changing trends in marrow transplantation for aplastic anemia (Review). *Bone Marrow Transplant* 10: 45-52, 1992.
  23. Sullivan, K.M., Mori, M., Sanders, J., Siadak, M., Witherspoon, R.P., **Anasetti, C.**, Appelbaum, F.R., Bensinger, W., Bowden, R., Buckner, C.D., Clark, J., Crawford, S., Deeg, H.J., Doney, K., Flowers, M., Hansen, J., Loughran, T., Martin, P., McDonald, G., Pepe, M., Petersen, F.B., Schuening, F., Stewart, P., Storb, R.: Late complications of allogeneic and autologous marrow transplantation (Review). *Bone Marrow Transplant* 10: 127-134, 1992.
  24. Hows, J.M., Szydlo, R., **Anasetti, C.**, Camitta, B., Gajewsky, J., Gluckman, E.: Unrelated donor marrow transplants for severe acquired aplastic anemia. *Bone Marrow Transplant* 10: 102-106, 1992.
  25. **Anasetti, C.**, Hansen, J.A.: Marrow transplantation in cancer therapy. *J. Exp. Med. (Japan)* 168: 333-343, 1992.
  26. Nemunaitis, J., **Anasetti, C.**, Buckner, C.D., Appelbaum, F.R., Shannon-Dorcy, K., Hansen, J., Singer,

- J.W.: Long-term follow-up of 103 patients who received recombinant human granulocyte-macrophage colony-stimulating factor after unrelated donor bone marrow transplantation (Letter). *Blood* 81: 865, 1993.
27. Nash, R.A., Pepe, M.S., Storb, R., **Anasetti, C.**, Appelbaum, F.R., Deeg, H.J., Doney, K., Martin, P.J., Sullivan, K.M., Witherspoon, R.P.: Risk factors for acute graft-versus-host disease associated with cyclosporine and methotrexate prophylaxis (Response to Letter to the Editor). *Blood* 81: 1973-1974, 1993.
  28. Mickelson, E.M., **Anasetti, C.**, Choo, S.Y., Longton, G.M., Petersdorf, E.W., Martin, P.J., Hansen, J.A.: Role of the mixed lymphocyte culture reaction in predicting acute graft-versus-host disease after marrow transplants from haploidentical and unrelated donors. *Transplant. Proc.* 25: 1239-1240, 1993.
  29. Petersdorf, E.W., Smith, A.G., Mickelson, E.M., Longton, G.M., **Anasetti, C.**, Choo, S.Y., Martin, P.J., Hansen, J.A.: Influence of HLA-DPB1 disparity on the development of acute graft-versus-host disease following unrelated donor marrow transplantation. *Transplant Proc.* 25: 1230-1231, 1993.
  30. Sanders, J.E., Storb, R., **Anasetti, C.**, Deeg, H.J., Doney, K., Sullivan, K.M., Witherspoon, R.P., Hansen, J.: Marrow transplant experience for children with severe aplastic anemia. *Am. J. Ped. Hematol. Oncol* 16: 43-49, 1994.
  31. Storb, R., Leisenring, W., Deeg, H.J., **Anasetti, C.**, Appelbaum, F., Bensinger, W., Buckner, C.D., Clift, R., Doney, K., Hansen, J., Martin, P., Sanders, J., Stewart, P., Sullivan, K., Thomas, E.D., Witherspoon, R.: Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia (Letter). *Blood* 83: 2749-2750, 1994.
  32. Deeg, H.J., **Anasetti, C.**, Petersdorf, E., Storb, R., Doney, K., Hansen, J.A., Sanders, J., Sullivan, K.M., Appelbaum, F.R.: Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors (Letter). *Blood* 83: 3417-3418, 1994.
  33. **Anasetti, C.**, Howe, C., Petersdorf, E.W., Martin, P.J., Hansen, J.A.: Marrow transplants from HLA-matched unrelated donors: an NMDP update and the Seattle experience. *Bone Marrow Transplant* 13: 693-695, 1994.
  34. **Anasetti, C.**, Hansen, J.A.: Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors. *Transfus Sci.* 15: 221-230, 1994.
  35. Appelbaum, F.R., Clift, R., Buckner, C.D., **Anasetti, C.**, Radich, J., Higano, T., Storb, R., Hansen, J., Thomas, E.D.: Allogeneic marrow transplantation for chronic myeloid leukemia. *Med. Oncol* 11: 69-74, 1994.
  36. Hansen, J.A., **Anasetti, C.**, Petersdorf, E., Clift, R.A., Martin, P.J.: Marrow transplants from unrelated donors. *Transplant. Proc.* 26: 1710-1712, 1994.
  37. **Anasetti, C.**, Petersdorf, E.W., Martin, P.J., Hansen, J.A.: Marrow transplantation from unrelated volunteer donors (Review). *Cancer Treat. Res.* 76: 137-168, 1995.
  38. Hansen, J.A., Petersdorf, E.W., Choo, S.Y., Martin, P.J., **Anasetti, C.**: Marrow transplantation from HLA partially matched relatives and unrelated donors. *Bone Marrow Transplant* 15: S128-S139, 1995.
  39. **Anasetti, C.**, Etzioni, R., Petersdorf, E.W., Martin, P.J., Hansen, J.A.: Marrow transplantation from unrelated volunteer donors. *Annu. Rev Med* 46: 169-179, 1995.
  40. Sierra, J., **Anasetti, C.**: Marrow transplantation from unrelated donors. *Curr. Opin. Hematol* 2: 444-451, 1995.
  41. Storb, R., **Anasetti, C.**, Appelbaum, F.R., Deeg, H.J., Doney, K., Martin, P., Nash, R., Sullivan, K., Witherspoon, R.: Immunosuppressive agents for prevention of graft-versus-host disease. *Bone Marrow Transplant* 15: S98-S103, 1995.
  42. Fay, J.W., Nash, R.A., Winegard, J., Prezepiorcka, D., Collins, R.H., **Anasetti, C.**, Devine, S., Piñeiro, L.A., Storb, R.F., Aro, R.M., Fitzsimmons, W.E.: FK506-based immunosuppression for prevention of graft-versus-host disease (GVHD) after unrelated marrow donor (UMD) transplantation. *Transplant Proc* 27: 1374, 1995.
  43. Appelbaum, F.R., Clift, R., Radich, J., **Anasetti, C.**, Buckner, C.D.: Bone marrow transplantation for chronic myelogenous leukemia (Review). *Semin. Oncol* 22: 405-411, 1995.
  44. **Anasetti, C.**: Marrow transplantation from unrelated volunteer donors. In: *American Society of Clinical Oncology Educational Book*, Washington, DC: Bristol-Myers Squibb Oncology, 76-78, 1995.
  45. Bensinger, W.I., Clift, R.A., **Anasetti, C.**, Appelbaum, F.R., Demirer, T., Rowley, S., Sandmaier, B.M., Torok-Storb, B., Storb, R., Buckner, C.D.: Transplantation of allogeneic peripheral blood stem cells

- mobilized by recombinant human granulocyte colony-stimulating factor. *Stem Cells* 14: 90-105, 1996.
46. Storb, R., Leisenring, W., **Anasetti, C.**, Appelbaum, F.R., Buckner, C.D., Bensinger, W.I., Chauncey, T., Clift, R.A., Deeg, H.J., Doney, K.C., Flowers, M.E.D., Hansen, J.A., Martin, P.J., Sanders, J.E., Sullivan, K.M., Witherspoon, R.P.: Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin (Letter to the Editor). *Blood* 89: 3890-3891, 1997.
  47. Hansen, J.A., Petersdorf, E., Martin, P.J., **Anasetti, C.**: Hematopoietic stem cell transplants from unrelated donors. *Immunol. Rev.* 157: 141-151, 1997.
  48. **Anasetti, C.**: Marrow transplantation from unrelated volunteer donors. *Bone Marrow Transplant* 19 (Suppl 2): S183-S185, 1997.
  49. Bjerke, J.W., **Anasetti, C.**: Marrow transplantation from unrelated volunteer donors. In: *Forum Trends in Experimental and Clinical Medicine, Volume 7.2*, Aaronson, S.A., Frati, L., Pinedo, H., and Santi, L. (eds.). Genova: Scoula Superiore di Oncologia e Scienze Biomediche, 146-155, 1997.
  50. Sullivan, K.M., **Anasetti, C.**, Horowitz, M., Rowlings, P.A., Petersdorf, E.W., Martin, P.J., Clift, R.A., Walters, M.C., Gooley, T., Sierra, J., Anderson, J.E., Bjerke, J., Siadak, M., Flowers, M.E.D., Nash, R.A., Sanders, J.E., Appelbaum, F.R., Storb, R., Hansen, J.A. Unrelated and HLA-nonidentical related donor marrow transplantation for thalassemia and leukemia: a combined report from the Seattle Marrow Transplant Team and the International Bone Marrow Transplant Registry. *Ann. NY Acad. Sci.* 885: 312-324, 1998.
  51. Lee, S.J., **Anasetti, C.**, Horowitz, M.M., Antin, J.H.: Initial therapy for CML: playing the odds. *J. Clin. Oncol* 16: 2897-2903, 1998.
  52. Martin, P.J., Schoch, G., Gooley, T., **Anasetti, C.**, Deeg, H.J., Nash, R., Sanders, J., Storb, R., Appelbaum, F.: Methods for assessment of graft-versus-host-disease (Letter). *Blood* 92: 3479-3480, 1998.
  53. Petersdorf, E., **Anasetti, C.**, Servida, P., Martin, P., Hansen, J. Effect of HLA matching on outcome of related and unrelated donor transplantation therapy for chronic myelogenous leukemia (Review). *Hematology - Oncology Clinics of North America* 12 : 107-121, 1998.
  54. Petersdorf, E.W., Mickelson, E.M., **Anasetti, C.**, Martin, P.J., Woolfrey, A.E., Hansen, J.A.: Effect of HLA mismatches on hematopoietic transplant outcomes. *Curr. Opin. Immunol* 11:521-526, 1999.
  55. Woolfrey, A., **Anasetti, C.**: Allogeneic hematopoietic stem-cell engraftment and graft failure. *Pediatr. Transplantation* 3 (suppl.1): 35-40, 1999.
  56. **Anasetti, C.**, Petersdorf, E.W., Martin, P.J., Woolfrey, A., Hansen, J.A.: Improving availability and safety of unrelated donor transplants. *Curr. Opin. Oncol.* 12: 121-126, 2000
  57. Mickelson, E.M., Petersdorf, E.W., **Anasetti, C.**, Martin, P., Woolfrey, A., Hansen, J.A.: HLA matching in hematopoietic cell transplantation. *Human Immunology* 61:92-100, 2000.
  58. **Anasetti, C.**: Transplantation of hematopoietic stem cells from alternate donors in acute myelogenous leukemia (Review). *Leukemia* 14: 502-504, 2000.
  59. Sierra, J., Bjerke, J., Hansen, J., Martin, P., Petersdorf, E., Woolfrey, A., **Anasetti, C.** Marrow transplants from unrelated donors as treatment for acute leukemia. *Leukemia & Lymphoma* 39: 495-507, 2000.
  60. **Anasetti, C.**, Petersdorf, E.W., Martin, P.J., Woolfrey, A., Hansen, J.A. Transplantation of hematopoietic stem cells from unrelated volunteer donors. *Transplant. Proc.* 32: 1539-1540, 2000.
  61. Carpenter, P.A., Tso, J.Y., Press, O.W., Yu, X.-Z., **Anasetti, C.** Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressive in vivo. *Transplant. Proc* 32: 1545-1546, 2000.
  62. Hansen, J.A., Petersdorf, E., Martin, P.J., Woolfrey, A., **Anasetti, C.** Impact of HLA matching on hematopoietic cell transplants from unrelated donors. *Vox Sang.* 78 (Suppl. 2): 269-271, 2000.
  63. Petersdorf, E., **Anasetti, C.**, Martin, P.J., Woolfrey, A., Smith, A., Mickelson, E., Malkki, M., Lin, M.-T., Hansen, J.A. Genomics of unrelated-donor hematopoietic cell transplantation. *Curr. Opin. Immunol* 13: 582-589, 2001.
  64. **Anasetti, C.**, Petersdorf, E.W., Martin, P.J., Woolfrey, A., Hansen, J.A. Trends in transplantation of hematopoietic stem cells from unrelated donors. *Curr. Opin. Hematol.* 8: 337-341, 2001.
  65. Yu, X.-Z., Carpenter, P., **Anasetti, C.** Advances in transplantation tolerance. *Lancet* 357: 1959-1963, 2001.
  66. Platzbecker, U., Gooley, T., **Anasetti, C.**, Appelbaum, F.R., Clurman, B., Doney, K., Chauncey, T.,

- Flowers, M.E.D., Myerson, D., Radich, J.P., Storb, R., Witherspoon, R.P., Deeg, H.J. Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation. *Leuk. Lymphoma* 43: 1409-1414, 2002.
67. **Anasetti, C.** Young is better if enough. *Blood* 97: 2921, 2001.
68. Yu, X.Z., Nitta, Y., Bidwell, S.J., **Anasetti, C.** Additive effects of anti-CD3 and anti-CD28 prolongation of allogeneic skin graft survival (Letter to Editor). *Transplantation* 72: 1862, 2001.
69. **Anasetti, C.** Advances in unrelated donor hematopoietic cell transplantation: improved matching and use of blood stem cells. *Haematologica* 87 (Suppl.): 1-3, 2002.
70. Petersdorf, E.W., **Anasetti, C.**, Martin, P.J., Hansen, J.A. Impact of molecular histocompatibility typing on outcome of unrelated donor hematopoietic cell transplantation. *Current Opinion in Organ Transplantation* 7: 279-285, 2002.
71. Rossi, M., Arpinati, M., Rondelli, D., **Anasetti, C.** Plasmacytoid dendritic cells: do they have a role in immune responses after hemtopoietic cell transplantation. *Hum. Immunol* 63: 1194-1200, 2002.
72. **Anasetti, C.** Photodynamic purging of immunoreactive T cells: the magic bullet? *Blood* 99: 3081, 2002.
73. Anderson, J.E., Appelbaum, F.R., Schoch, G., Gooley, T., **Anasetti, C.**, Bensinger, W.I., Bryant, E., Buckner, C.D., Chauncey, T., Clift, R.A., Deeg, H.J., Doney, K., Flowers, M., Hansen, J.A., Martin, P.J., Matthews, D.C., Nash, R.A., Sanders, J.E., Shulman, H., Sullivan, K.M., Witherspoon, R.P., Storb, R. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors (*JCO* 1996 14: 220-226) [Author Update]. *Classic Papers and Current Comments* 7: 237-244, 2002.
74. Petersdorf, E.W., **Anasetti, C.**, Martin, P.J., Hansen, J.A. Tissue typing in support of unrelated hemtopoieitc cell transplantation (Review). *Tissue Antigens* 61: 1-11, 2003.
75. **Anasetti, C.** Advances in unrelated donor hematopoietic cell transplantation. *Haematologica* 88: 246-249, 2003.
76. **Anasetti, C.** Acquired tolerance to renal allografts in humans (Editorial). *Am. J. Transplant* 3: 243-244, 2003.
77. Kiem, H.-P., **Anasetti, C.** Sirolimus and tacrolimus binding proteins: double-edged swords for GVHD prophylaxis. *Blood* 102: 1562, 2003.
78. Hurley, C.K., Lowe, L.A.B., Logan, B., Karanes, C., **Anasetti, C.**, Weisdorf, D., Confer, D.L. National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplants. *Biol. Blood Marrow Transplant* 9: 610-615, 2003.
79. Sierra, J., **Anasetti, C.** Hematopoietic transplantation from adult unrelated donors. *Current Opinion in Organ Transplantation* 8: 99-108, 2003.
80. Arpinati, M., Chirumbolo, G., Urbini, B., Perrone, G., Rondelli, D., **Anasetti, C.** Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation. *Transpl. Immunol* 11: 345-356, 2003.
81. **Anasetti, C.** Advances in the Prevention of Graft-Versus-Host Disease after Hematopoietic Cell Transplantation. *Transplantation* 77: S79-S83, 2004.
82. **Anasetti, C.** Thrombopoietin and the mysteries of plasmacytoid dendritic cells. *Blood* 103: 2433, 2004.
83. Field T, **Anasetti C.** Selection of Unrelated Donors for Hematopoietic Cell Transplantation. *Curr Hematol Rep* 4: 270-275, 2005.
84. **Anasetti C.**, Yu, X., Memory stem cells sustain disease. *Nature Medicine* 12: 1282-1283, 2005.
85. **Anasetti C.** The 2006 BBMT Education Supplement. *Biol. Blood Marrow Transplant* 12 (Suppl 1):1, 2006.
86. Albert MH, **Anasetti C**, Yu XZ. T regulatory cells as an immunotherapy for transplantation. *Expert Opin. Biol. Ther* 6:315-24, 2006.
87. Jones, R.B., **Anasetti, C.**, Appel, P., DiPersio, J., Heslop, H., Lemaistre, F., Silver, S., Sirilla, J., Stiff, P., ASBMT Committee Report: White Paper on Measurement of Quality Outcomes. *Biol. Blood Marrow Transplant* 12:594-597, 2006.
88. **Anasetti C.**, Perkins J., Nieder ML, Field T., Are matched unrelated donor transplants justified for AML in CR1? *Best Practice & Research Clinical Haematology* 19:321-8, 2006.
89. Kharfan-Dabaja MA, Ayala E, Green J, Rojiani A, Murtagh FR, **Anasetti C**. Two cases of progressive multifocal leukoencephalopathy after allogeneic cell transplantation and a review of the literature. *Bone Marrow Transplant* 39:101-7, 2007.

90. Kharfan-Dabaja MA, **Anasetti C**, Ferrara JL. Sympathectomy protects denervated skin from graft-versus-host disease. *Biol. Blood Marrow Transplant* 13:369-70, 2007.
91. Kharfan-Dabaja MA, **Anasetti C**, Santos ES. Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept. *Biol Blood Marrow Transplant* 4:373-85, 2007.
92. **Anasetti C**, Mule JJ, To ablate or not to ablate? HSCS in the T cell driver's seat. *J. Clin. Invest* 2:306-10, 2007. PMID:PMC1783831
93. Ferrara, JL, **Anasetti C**, Stadtmauer E, Antin J, Wingard J, Lee S, Levine J, Schultz K, Appelbaum F, Negrin R, Giralt S, Bredeson C, Heslop H, Horowitz M. Blood and Marrow Transplant Clinical Trials Network State of the Science symposium 2007. *Biol. Blood Marrow Transplant* 13:1268-85, 2007.
94. Kamani N, Spellman S, Hurley CK, Barker JN, Smith FO, Oudshoorn M, Bray R, Smith A, Williams TM, Logan B, Eapen M, **Anasetti C**, Setterholm M, Confer DL. National Marrow Donor Program. State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants. *Biol. Blood Marrow Transplant* 14:1-6, 2008.
95. **Anasetti, C**. Chemotherapy or Allografting for Young Adults with High Risk ALL? *Blood* 111:5755. 2008.
96. **Anasetti, C**. What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation? *Best Pract & Res Clinl Haematol* 8:21:691-7. 2008
97. **Anasetti C**. Selecting donor recipients. *Biol. Blood Marrow Transplant.* 15:393-4. 2009
98. Pidala J, **Anasetti C** and Jim H. Quality of life after allogeneic hematopoietic cell transplantation. *Blood* 114:7-19. 2009. PMID:PMC2710956.
99. Gajewski JL, LeMaistre CF, Silver SM, Lill MC, Selby GB, Horowitz MM, Rizzo JD, Heslop HE, **Anasetti C**, and Maziarz RT. Impending challenges in the hematopoietic stem cell transplantation physician workforce. *Biol. Blood Marrow Transplant* 5:1493-501 2009.
100. Pidala J, Bloom GC, Enkemann S, Eschrich S, Lancaster J, and **Anasetti C**. Biomarkers to discern transplantation tolerance after allogeneic hematopoietic cell transplantation. *Biol. Blood Marrow Transplant* 16:729-38. 2010.
101. Pidala J, **Anasetti C**. Can antigen-specific regulatory T cells protect against graft vs. host disease and spare anti-malignancy alloresponse? *Haematologica* 95:660-5. 2010. PMID: PMC2857197
102. Pidala J, **Anasetti C**, and Jim H. Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention. *Br. J. Haematol* 148:373-85, 2010. PMID: PMC2810350
103. Pidala J, and **Anasetti C**. Glucocorticoid-refractory acute graft vs. Host disease. *Biol Blood Marrow Transplant* 16:1504-18, 2010.
104. Schriber JR, **Anasetti C**, Heslop HE, Leahigh AK. Preparing for Growth: Current Capacity and Challenges in Hematopoietic Stem Cell Transplant Programs. *Biol. Blood Marrow Transplant* 16:595-7. 2010.
105. Tedeschi SK, Savani BN, Jagasia M, Engelhardt B, **Anasetti C**, Barrett AJ, Lee S. Time to consider HPV vaccination after allogeneic stem cell transplantation. *Biol. Blood Marrow Transplant* 16:1033-6. 2010.
106. Kharfan-Dabaja MA, Pidala J, **Anasetti C**. Thrombotic microangiopathy after GVHD prophylaxis with tacrolimus/sirolimus: a call for use of consensus definition in reporting. *Blood* 115:4316-7, 2010.
107. Pidala J, **Anasetti C**. In response to: Role of Extracorporeal Photopheresis (ECP) in Treatment of Steroid-refractory Acute Graft-versus-host Disease. *Biol. Blood Marrow Transplant* 16:1749, 2010.
108. Cutler C, Kesselheim A, Gabardi S, Andersson BS, Carpenter P, Khoury HJ, Litzow M, Rowley SD, Lanum S, Leather H, Tina Shih YC, Gale RP, Wingard JR, Appelbaum FR, **Anasetti C**. Generic immunosuppressants in hematopoietic celltransplantation. *Biol Blood Marrow Transplant* 17:285-90, 2011.
109. Perez L, **Anasetti C**, Pidala J. Have we improved in preventing and treating acute graft-versus-host disease? *Curr Opin Hematol* 18:408-13, 2011.
110. Majhail NS, Murphy EA, Denzen EM, Ferguson SS, **Anasetti C**, Bracey A, Burns L, Champlin R, Hubbard N, Markowitz M, Maziarz RT, Medoff E, Neumann J, Schmit-Pokorny K, Weisdorf DJ, Yolin Raley DS, Chell J, Snyder EL. The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: A Health Care Resource and Infrastructure Assessment. *Biol Blood Marrow Transplant* 18:172-82, 2012.
111. **Anasetti C**, Aversa F, Brunstein CG. Back to the future: mismatched unrelated donor, haploidentical related donor, or unrelated umbilical cord blood transplantation? *Biol Blood Marrow Transplant.*

18:S161-5, 2012.

112. **Anasetti C**. The ever elusive permissive mismatch. *Biol Blood Marrow Transplant*. 18:657-8, 2012.
113. Denzen EM, Majhail NS, Ferguson SS, **Anasetti C**, Bracey A, Burns L, Champlin R, Chell J, Leather H, Lill M, Maziarz RT, Medoff E, Neumann J, Schmit-Pokorny K, Snyder EL, Wiggins L, Yolin Raley DS, Murphy EA. Hematopoietic Cell Transplantation in 2020: Summary of Year II Recommendations of the National Marrow Donor Program's System Capacity Initiative. *Biol Blood Marrow Transplant*. 19:4-11, 2013.
114. **Anasetti C**, Logan BR, Confer DL; Blood and Marrow Transplant Clinical Trials Network. Peripheral-blood versus bone marrow stem cells. *N Engl J Med*. 368:288, 2013.

## **DOCUMENTATION OF NATIONAL AND INTERNATIONAL REPUTATION**

### **1. Oral Presentation of Original or Plenary Papers at National or International Meetings:**

- |          |  |
|----------|--|
| Nov 1985 | "International Advanced Course on Human Preleukemia", Rome, Italy: Oral presentation on "Allogeneic marrow transplantation in the treatment of preleukemia".   |
| Dec 1985 | "27th American Society of Hematology Annual Meeting", New Orleans, LA: Oral presentation on "Marrow transplantation for 50 untransfused patients with severe aplastic anemia".   |
| Sep 1986 | "3rd International Workshop and Conference on Human Leukocyte Differentiation Antigens", Oxford, UK: Oral presentation on "Enhancement of natural killing in large granular lymphocytes by binding of monoclonal antibodies to CD2 and CD16".  |
| Feb 1989 | "4th International Leukocyte Antigen Workshop", Vienna, Austria: Oral presentation on "Activation of NK cells by CD2 binding to LFA-3 on target T cells".  |
| Sep 1989 | "15th Annual Meeting of the American Society for Histocompatibility and Immunogenetics", Toronto, Canada: Oral presentation on "Graft-versus-host reaction, relapse and survival after HLA-nonidentical marrow transplants for malignancy".  |
| Dec 1989 | "31st American Society of Hematology Annual Meeting", Atlanta, GA: Oral presentation on "Alloantigen specific T suppressor-inducer and T suppressor-effector cells can be induced by blocking the IL-2 receptor".  |
| Apr 1990 | "19th Annual Meeting of International Society of Experimental Hematology", Seattle, WA: Oral presentation on "Effect of post-transplant immunosuppression on relapse and survival after marrow transplantation".   |
| May 1990 | "16th Annual Meeting of the European Bone Marrow Transplant Group, The Hague, The Netherlands: Oral presentation on "Treatment of acute GVHD with anti-CD3 antibody BC3".  |
| May 1990 | "9th Annual Meeting of the American Society of Transplant Physicians", Chicago, IL: Oral presentation on "Prophylaxis of graft-versus-host disease by in vivo administration of a murine anti-IL-2 receptor antibody (Anti-CD25)".   |
| Jul 1991 | "20th Annual Meeting of the International Society of Experimental Hematology", Parma, Italy: Oral presentation on "Unrelated donor or autologous marrow transplantation for treatment of acute leukemia".  |
| Apr 1992 | FASEB Meeting, Anaheim, CA: Oral presentation on "Induction of T cell tolerance by hyperstimulation of the T cell receptor".   |
| Jul 1992 | Annual Meeting of the "21st International Society of Experimental Hematology", Providence RI: Oral presentation on "Marrow transplantation from unrelated donors for treatment of CML".  |
| Dec 1992 | "34th American Society of Hematology Annual Meeting", Anaheim, CA: Oral presentation on "Treatment of acute graft-versus-host disease with a humanized monoclonal antibody specific for the IL-2 receptor".  |
| Dec 1993 | "35th American Society of Hematology Annual Meeting", St. Louis, MO: Oral presentation on "Phase III study of rhGM-CSF in allogeneic marrow transplantation from unrelated donors".  |
| Dec 1994 | "36th American Society of Hematology Annual Meeting", Nashville, TN: Oral presentation on "Engraftment of allogeneic hematopoietic stem cells in patients conditioned only with anti-CD3 antibody and prednisone".   |
| Dec 1995 | "37th American Society of Hematology Annual Meeting", Seattle, WA: Oral presentation on "A phase II/III randomized, double blind placebo-controlled multicenter trial of HAT for prevention of acute graft-versus-host disease in recipients of marrow transplants from unrelated donors". |
| Dec 2001 | 43rd American Society of Hematology. Orlando, FL. Oral presentation: "Depletion of   |



- alloreactive T cells by anti-CD3 therapy prevents GVHD in mice.”
- Jun 2005 Roswell Park Cancer Institute Medical Grand Rounds, Buffalo, NY. Oral presentation: “Peripheral T cell tolerance after BMT”
- Dec. 2007 American Society for Hematology (ASH), Meet the Experts Session, “Alternative Donor Transplants”
- Dec. 2011 “53<sup>rd</sup> American Society for Hematology Annual Meeting”, San Diego, CA. Plenary Scientific Session: "Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial"
- Feb. 2012 BMT Tandem Meetings, San Diego, CA. BMT CTN 0201 Peripheral Blood vs Bone Marrow. This presentation is part of the (BMTCTN) BMT CTN Investigators Meeting: 0801, 1101, 0201 and 0401 session.

## 2. Invited Lectures at National Meetings:

- May 1990 College of American Pathologists, Annual Meeting, Santa Fe, NM: Lecture on “The clinical laboratory in bone marrow transplantation”.
- May 1991 “American Society of Histocompatibility and Immunogenetics Regional Education Workshop”, Seattle, WA: Lecture on “Unrelated donor marrow transplantation”.
- Oct 1991 NMDP Council Meeting, Minneapolis, MN: Lecture on “Who should get an unrelated BMT for acute leukemia?”
- Jan 1992 Keystone Symposium, Workshop “Unrelated Donor Bone Marrow Transplants”, Keystone, CO: Lecture on “Transplants from family members partially matched for HLA”.
- Oct 1992 NMDP Council Meeting, Minneapolis, MN: Lecture on “Risk factors for acute GVHD and death after unrelated donor transplants in one center”.
- Dec 1992 “34th American Society of Hematology”, Educational Session, Anaheim, CA: Lecture on “Bone marrow transplantation”.
- Oct 1993 NMDP Council Meeting, Minn., MN: Lecture on “CMV disease in unrelated donor transplants”.
- Jan 1994 Keystone Symposium Meeting, Keystone, CO: Lecture on “Prevention of CMV after unrelated BMT”.
- Nov 1995 “American Society of Clinical Oncology, Fall Conference”, Washington, D.C: Lecture on “Allogeneic marrow transplantation for treatment of acute leukemia”.
- Feb 1996 “6th International Conference on Lymphocyte Activation and Immune Regulation”, Newport Beach, CA: Lecture on “Cell cycle control of T cell apoptosis induced by activation through the T cell antigen receptor”.
- Dec 1996 American Society of Hematology, NMDP Satellite Symposium, Orlando, FL: Lecture on “Marrow transplantation from unrelated volunteer donors”.
- Dec 1997 ASH “superfriday” Symposium, San Diego, CA. Presentation: “New Drugs in the Prevention and Treatment of Acute Graft-Versus-Host Disease”
- Sep 1998 5<sup>th</sup> International Symposium on Dendritic Cells in Fundamental and Clinical Immunology. Pittsburg, PA. Lecture: “HLA in Hematopoietic Stem Cell Transplantation.”
- Mar 1998 ASBMT Annual Meeting: Presentation: “Immunogenetics of Haploidentical and Unrelated Stem Cell Transplantation.”
- Aug 1998 First Annual APAO Oncology Symposium. Presentation: “New Advances in Allogeneic Stem Cell Transplantation”
- Feb 1999 Tandem BMT Meetings, IBMTR/ABMTR, Keystone, CO. Presentation: “Tolerogenic Potential of Mobilized Progenitor Cells”; 2) “Selective Depletion of Activated T-cells by Engineered Antibodies.”
- Apr 1999 Acute Leukemia Forum '99, San Francisco, CA. Presentation: “Bone Marrow Transplantation from Alternate Donors in AML.”
- May 2000 American Society of Clinical Oncology (ASCO) Annual Meeting, New Orleans, LA. Session Title: “Nonmyeloablative-Related and Unrelated Hematopoietic Stem-Cell Transplants.”
- Sept 2000 Thirteenth Annual National Marrow Donor Program (NMDP) Council Meeting, Minneapolis, MN. Presentation: “Stem Cell Options for Second Transplants.”
- Dec 2000 The American Society of Hematology 42<sup>nd</sup> Annual Meeting and Expo, San Francisco, CA.

Feb 2001 Presentation: "Use of Unrelated Donors for Stem Cell Transplantation."  
Tandem BMT Meetings IBMTR/ABMTR, Keystone, CO. Point/Counterpoint Session: Sources of Stem Cells "Unrelated Donors."

Jun 2001 2<sup>nd</sup> Joint International Psoriasis Symposium & European Congress on Psoriasis, San Francisco, CA. Presentation: "The Use of Immunosuppressives in the Treatment of Graft-Versus-Host Disease: a Model for T-cell-Mediated Diseases."

Nov 2001 National Marrow Donor Program (NMDP) Council Meeting, Minneapolis, MN. Presentation: Scientific Session – "Analysis of NMDP's PBSC Transplants."

Dec 2001 ASH Novel Advances in Targeted Cellular Therapy in Hematologic Malignancies "Corporate Friday" Symposium, Orlando, FL. Presentation: "Current and Future Treatment of Graft-Versus-Host Disease-Targeting CD3."

Oct 2002 American Association of Blood Banks 55<sup>th</sup> Annual Meeting; Orlando, FL. Presentation: "Factors Determining the Success of Unrelated Donor Stem Cell Transplantation."

Dec 2002 ASH National Marrow Donor Program Corporate Symposium, Philadelphia, PA. Chair: "Current Perspectives on Unrelated Donor Stem Cell Transplantation."

Jan 2003 IBMTR-ABMTR Tandem BMT Meetings at Keystone; Keystone, CO. Presentation: 1) "CD28 Targeted Therapy for GVHD Prevention." Workshop: 2) PBSC from Unrelated Donors: Can We Exploit Them to Improve Outcome?"

Apr 2003 National Marrow Donor Program Transplant Center Spring Meeting, San Diego, CA. Presentation: "PBSC vs. Marrow: Cell Dose and Outcomes."

May 2003 University of California San Diego School of Medicine - 11th International Symposium on Recent Advances in Stem Cell Transplantation. Presentation: "Novel Approaches to Prevention of GVHD."

Oct 2003 American Society for Histocompatibility & Immunogenetics (ASHI) 29<sup>th</sup> Annual Meeting, Miami Beach, FL. Presentation: "Donor Matching in Blood Marrow Transplantation."

Nov 2003 National Marrow Donor Program Council Meeting, Minneapolis, MN. Presentation: "PBSC vs. Marrow Randomized Trial Overview."

Feb 2004 ASBMT Tandem BMT Meetings, Orlando, FL. NMDP Workshop Panelist - Strategies in Unrelated Donor Selection.

Dec 2004 American Society of Hematology, San Diego, CA. Presentation: "Problems and Successes of Unrelated Hematopoietic Stem Cell Transplantation."

Oct 2005 AABB Annual Meeting, Seattle, WA. Presentation: "Marrow vs Blood Stem Cells Transplantation from Unrelated Donors."

Apr 2005 Acute Leukemia Forum 2005, San Francisco, CA. Lecture on "Are Matched Unrelated Donor Transplants Justified for AML in CR1?"

Nov 2005 NMDP Council Meeting, Minn., MN: Lecture on "Blood vs Marrow Transplants from Unrelated Donors"

Jun 2006 American Society of Clinical Oncology (ASCO), Scientific Session Chair, Atlanta, GA. Presentation: "Leukemia, Myelodysplasia and Transplantation."

Feb 2007 American Society of Blood and Marrow Transplantation, Breakfast Conference Chair on "Future conditioning Regimes in Hematopoietic Cell Transplantation", and presentation on "Regimes for Allografting".

Dec 2007 The American Society of Hematology 49th Annual Meeting and Expo, Atlanta, GA. Presentation: "Alternative Donor Transplants".

Apr 2008 Acute Leukemia Forum 2008: San Francisco, CA. Presentation "What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation?"

Dec 2008 The American Society of Hematology 50th Annual Meeting and Expo, San Francisco, CA. Presentation: "Comparing Outcomes from Unrelated and Related Donor HCT"

Feb 2009 ASBMT Tandem Annual Meeting, Tampa, FL. Presentation "Coverage for Clinical Trials" & "Acute GVHD"

May 2009 ASCO Annual Meeting, Chicago, IL. Presentation "Novel Immunotherapeutic Approaches for Improving Outcomes Following Allogeneic Stem Cell Transplantation"

Oct 2010 NMDP Council Meeting, Minneapolis, MN: "The role of patient ethnicity in finding an HLA matched unrelated donor."

Dec 2010 BMT Tandem , Honolulu, HI Presentation "Donor/patient selection."

- Mar. 2011 Advanced HLA Technical Workshop, Punta Cana, Dominican Republic, Presentation, "The art and science of HLA matching."
- Feb. 2012 BMT Tandem Meetings, San Diego, CA. Presenting Author: Mismatched Unrelated Donor Transplantation Presentation.
- June. 2012 ASCO Annual Meeting, Chicago, IL. Presentation "Increased Incidence of Chronic Graft-versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial (ASH Abstract #: 39189)"
- Nov. 2012 3<sup>rd</sup> Annual GVHD Symposium, Cleveland, OH. Presentation: "Stem Cell Graft Sources and GVHD".
- Oct. 2013 Mayo School of Continuous Professional Development Hematologic Malignancies: New Therapies and the Evolving Role of Transplant. Chicago, IL. Lecture Title: "Stem Cell Sources"

### 3. Invited Lectures at International or Foreign Meetings:

- Oct 1987 Workshop "T cell activation in health and disease", Oxford, UK: Lecture on "MAb in vivo for modifying the course of Bone Marrow Transplantation".
- Jun 1989 "Annual Meeting of the Chinese Medical Association", Taipei, Taiwan: Lecture on "Bone Marrow Transplantation".
- Sep 1990 Meeting on "Marrow transplantation from unrelated donors", St. Vincent, Italy: Lecture on "Marrow transplantation from an unrelated donor or from a partially HLA-matched family member: advantages and disadvantages".
- Oct 1990 Course "Transplantation 1990", L'Aquila, Italy: Lecture on "HLA in marrow transplantation".
- Nov 1991 "11th International Histocompatibility Workshop and Conference", Yokohama, Japan: Lecture on "HLA in marrow transplantation".
- Feb 1992 Course "Transplantation 1992", L'Aquila, Italy: Lecture on "Bone marrow transplantation from unrelated individuals".
- Apr 1992 "Transplantation Society of the Philippines Convention", Manila, Philippines: Lectures on "Bone marrow transplantation for acute leukemia" and "BMT from donors other than HLA-identical siblings".
- May 1992 "AML Mini-Symposium", Vancouver, British Columbia: Lecture on "Marrow transplantation from unrelated donors for therapy of acute leukemia".
- Sep 1992 "International Symposium on Bone Marrow Transplantation from Alternative Donors" Pavia, Italy: Lecture on "Marrow transplantation from unrelated donors".
- Oct 1992 "Second International Conference on Chronic Myeloid Leukemia", Bologna, Italy: Lecture on "Allogeneic BMT-Can one use mismatched related donors?".
- Sep 1993 "First International Symposium on Cytokines in Bone Marrow Transplantation", Christchurch, New Zealand: Lecture on "Effect of HLA mismatching in marrow transplantation from unrelated donors".
- Sep 1993 "1993 International Congress on Bone Marrow Transplantation" Beijing China: Lecture on "Unrelated donor marrow transplantation".
- Sep 1993 "French Hematologists' National Meeting", Paris, France: Lecture on "GM-CSF in unrelated donor transplants".
- Oct 1993 "14th National Congress of the Brazilian College of Hematology", Curitiba, Brazil: Lecture on "Marrow transplantation from unrelated volunteer donors".
- Dec 1993 "16th Japanese Society for Bone Marrow Transplantation", Yokohama, Japan: Lecture on "Marrow transplantation from unrelated donors".
- May 1994 "Unrelated Donor Marrow Transplantation", Madrid, Spain: Lecture on "Marrow transplantation from unrelated volunteer donors".
- Jun 1994 "ERASME Biomedical Conference", Brussels, Belgium: Lecture on "The future of bone marrow transplantation".
- Jun 1994 "National Convention of Pediatric Oncology", Pisa, Italy: Lecture on "Marrow transplantation from unrelated volunteer donors".

Oct 1994 "XXI Brazilian Hematology and Hemotherapy Congress", Sao Paulo, Brazil: Lectures on "International marrow donor program", "Results of unrelated donor transplants", "New approaches for the prevention and treatment of GVHD".

Feb 1996 Meeting on "Clinical and Fundamental Immunology", Marseille, France: Lecture on "T cell tolerance in allogeneic stem cell transplantation".

Apr 1996 "Second International Course on Bone Marrow Transplantation in Children", Erice, Sicily: Lecture on "Unrelated donor bone marrow transplantation for childhood leukemia".

Aug 1996 "Annual Meeting of the Society of Hematology of Thailand", Bangkok, Thailand: Lecture on "Unrelated donor bone marrow transplantation".

Aug 1996 "26th Congress of the International Society of Haematology", Presidential Symposium, Singapore: Lecture on "Unrelated donor marrow transplantation".

Sep 1996 "Bone Marrow Transplantation in Thalassemia", Pesaro, Italy: Lecture on "Marrow transplantation from unrelated volunteer donors".

Feb 1997 "Acute Leukemia", Munster, Germany: Lecture on "Unrelated donor transplantation for treatment of acute leukemia".

Jun 1998 XXXIII Congress of the Italian Society of Blood Transfusion. Pescara, Italy. Lecture: "Allogeneic Transplant in Patients with a Mismatched or Unrelated Donor."

June 1998 International Symposium on Advances in Hematology, Barcelona, Spain. Presentation: "Donor Selection. Compatibility Required and Clinical Impact of HLA-disparity."

Nov 1998 Donazioni Piemontesi Di Midollo Osseo. Torino, Italy. Lecture: "Bone Marrow Transplants from Unrelated Donors."

Apr 1999 16th Annual Bone Marrow Transplant Symposium. Pesoro, Italy. Presentation: "Unrelated Donor Marrow Transplantation."

Jun 1999 8th International Workshop on CML and Interferon. Weinheim, Germany. Presentation: "Results of Transplantation in CML after Nonmyeloablative Conditioning."

Jul 1999 International Symposium on Chronic Myeloid Leukemia, Biarritz, France. Presentation: "Marrow Transplantation from Unrelated Volunteer Donors for Treatment of Chronic Myelogenous Leukemia."

Sept 1999 6th Congress of the Asian Society of Transplantation, Suntec City, Singapore. Presentation: 1) "Unrelated Donor Marrow Transplantation: Origin and Future Directions;" 2) "New Strategies in Graft Versus Host Disease and Tolerisation."

Sept. 1999 Italian Hematology Society 37th Congress, Torino, Italy. Lecture: "Stem Cell Transplantation from Volunteer Donors."

Nov 1999 Stem Cell Transplantation Results, New Perspectives, Milan, Italy. Presentation: "Bone Marrow Transplantation from Unrelated Donors."

Apr 2000 European Group for Blood and Marrow Transplantation, Milan, Italy. Presentation "HLA and Unrelated Transplants."

Jun 2000 3rd International Conference – The Jubilee Meeting on Chronic Myeloid Leukemia, Bologna, Italy. Presentation: "Allogeneic Transplantation from Family or Unrelated Donor."

Oct 2000 15th Annual Scientific Meeting of the Society for Biological Therapy, Seattle, WA. Presentation: Trial - Preclinical Trial Results "Humanized anti-CD3."

Nov 2000 EBMT 3rd International Symposium on Allogeneic Peripheral Blood Progenitor Cell Transplantation, Montreux, Switzerland. Presentation: "CD34 Cell Dose and Survival after Allogeneic Transplantation."

Feb 2001 "Avances en el Trasplante de Progenitores Hematopoyeticos", Madrid, Spain. Lecture: "Unrelated Donor Marrow Transplantation. The Seattle Experience."

Mar 2001 9th International Symposium on Recent Advances in Hematopoietic Stem cell Transplantation, San Diego, CA. Presentation: "Advances in Allogeneic Stem Cell Transplantation." "Of Mice and Men: Targeting the T-Cell Receptor to Facilitate Tolerance."

May 2002 "The Present and Future of Stem Cell Transplantation, Padova, Italy. Lecture: "Results in Bone Marrow Transplant from Unrelated Donor."

Sept 2002 AIBT 9th National Meeting, Pesaro, Italy. "Lecture: Unrelated Transplant in Hematopoietic Malignancies."

Oct 2002 European Blood and Marrow in Transplantation Workshop: "New Perspectives in Allogeneic Transplantation of Hematopoietic Cells", Milan, Italy. Lecture: "Humanized anti-CD3 Antibody for the Treatment of Steroid Resistant Acute GVHD."

Jul 2003 EBMT: Acute and Chronic GVHD in 2003. News on Mechanism & Prevention, Istanbul, Turkey. Presentation: "Chronic GVHD Following Unrelated Marrow Transplant. Chair - Workshop: HLA Typing 10/10 versus 12/12.

Oct 2004 European Blood and Marrow in Transplantation Meeting, Milan, Italy. "Humanized anti-CD3 Antibody for the Treatment of Steroid Resistant Acute GVHD."

Mar 2006 European Blood and Marrow in Transplantation Meeting, Hamburg, Germany. Chair, "Cellular therapy of infections and malignant disease"

Nov 2009 Universita Cattolica del Sacro Cuore - Congress New Drugs Rome, Italy. "Role and Timing of Transplantation".

Nov 2009 Italian Bone Marrow Donor Registry Genova, Cotone Congressi "Marrow vs Blood"

May 2010 University of Michigan, Grand Rounds Lecture, "Graft-versus-Host Disease: A Case for Personalized Medicine".

June 2010 7<sup>th</sup> Meeting of the European Blood and Marrow Transplantation, Helsinki, Finland. "Will sirolimus fulfill the promise to control GVHD?"

Mar. 2011 Fourth International Symposium on Secondary leukemia and leukemogenesis, Rome, Italy Presentation "Comparing hematopoietic stem cell transplantation in MDS/AML, t-AML and elderly AML USA experience."

Sept. 2012 The Anthony Nolan Research Institute Special Event "Donor selection and outcome of haematopoietic stem cell transplantation." London, United Kingdom.

Oct. 2012 "74th Annual Meeting of the Japanese Society of Hematology", Tokyo, Japan. Presentation title: BMT-CTN randomized multicenter trial of unrelated donor transplantation: Peripheral blood stem cells versus bone marrow.

Oct. 2012 "74th Annual Meeting of the Japanese Society of Hematology", Kyoto, Japan. Luncheon Seminar: "The choice of stem cell source for unrelated SCT".

June 2013 "18th Congress of the European Hematology Association", Stockholm, Sweden. "Immunogenetics in SCT"

Oct 2013 Canadian Blood and Marrow Transplantation Group GVHD Symposium. Montreal, Quebec Canada, "Donor Sources and GVHD".

#### 4. Visiting Professorship at National or Foreign Medical Schools or Medical Care Centers:

Jun 1989 Nagoya University School of Medicine, Nagoya, Japan: Lecture on "HLA in marrow transplantation".

Apr 1992 The National Institute of Kidney Disease, Manila, Philippines.

Apr 1992 University of Hong Kong, Queen Mary Hospital, Hong Kong: Lecture on "Marrow transplantation from unrelated donors".

Feb 1993 Nebraska Leukemia Network, University of Nebraska, Omaha, NE: Lecture on "Unrelated marrow transplantation".

Apr 1993 The University of Utah, Salt Lake City, UT: Lecture on "T cell tolerance".

May 1993 The University of Genoa, Genova, Italy: Lecture on "Unrelated donor transplants".

Jan 1994 Thomas Jefferson University/Jefferson Cancer Center, Philadelphia, PA: Lecture on "Tolerance in allogeneic marrow transplantation".

Apr 1994 Health Ministry's Honorary Visiting Consultant, Singapore: Consultant for the clinical program in hematology and transplantation.

Mar 1995 West Virginia University, Morgantown, WV, Lecture, "Allogeneic marrow transplantation".

Mar 1995 Mayo Clinic, Rochester, MN: Lecture on "Tolerance to allogeneic hematopoietic stem cells in man".

Oct 1995 Auburn General Hospital, Auburn, WA: Lecture, "Bone marrow transplantation: 1995".

Sep 1996 University of Bologna, Bologna, Italy: Lecture on "Immunological Tolerance".

Sep 1996 University of Rome, Rome, Italy: Lecture on "Marrow Transplantation from HLA non-identical related or unrelated donors".

Apr 1997 Henry Ford Hospital, Detroit, MI: Lecture on "Allogeneic marrow transplantation".

Apr 2000 Palermo, Italy. Lecutre: "Transplant from Volunteer Donor: Past, Present and Future."

May 2001 Washington University School of Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, St. Louis, MO. Presentation: "Marrow Transplants from

Unrelated Volunteer Donors.”

May 2001 Diabetes Endocrinology Research Center, Seattle, WA. Presentation: “Human Islet Transplantation and Tolerance Induction.”

Oct 2001 Vanderbilt University Medical Center, Department of Medicine, Division of Hematology/Oncology, Division of Continuing Medical Education. Presentation: “Hematopoietic Stem Cell Transplantation From Related or Unrelated Donors: Current Status and Future Developments.”

June 2002 University of California San Diego, Seminar Title: “Peripheral T Cell Tolerance.”

Oct 2002 Brescia School of Medicine, Brescia, Italy. Lecture: “New Perspectives in Allogeneic Transplantation of Hematopoietic Cells.”

May 2003 University of Nebraska Medical Center, Omaha, NB, Hematology/Oncology Research Conference. Presentation: “Overcoming the Barrier of Allogeneic Transplantation.”

Jun 2003 Memorial Sloan-Kettering Cancer Center Division Hematologic Oncology, New York, NY. Presentation: Hematology/Solid Tumor Oncology Combined Grand Rounds lecture.

Oct 2003 Pennsylvania State University College of Medicine, Hershey, PA. Presentation: “Overcoming the Barrier of Allogeneic Transplantation.”

Feb 2004 Winship Cancer Institute, Elkin Cancer Biology Seminar Series; Atlanta, GA. Presentation: “Donor Selection for Hematopoietic Cell Transplantation.”

Nov 2004 National Institute of Health Study Section, Bethesda, MD. Grand Rounds: “GVHD prevention by selective depletion of the alloreactive T cell repertoire.”

Nov 2004 NIH/NHLBI Fellowship Conference, Bethesda, MD. Presentation: “Challenges in Allogeneic Hematopoietic Cell Transplantation: From Bench to Bedside.”

Jan 2005 MD Anderson BMT Meetings, Houston, TX. Presentation: “Challenges in Allogeneic Hematopoietic Cell Transplantation: From Bench to Bedside.”

Feb 2005 Halifax Medical Center Tumor Conference, Daytona Beach, FL. Presentation: “Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of hematopoietic Malignancies.”

Jun 2005 Roswell Park, Buffalo, NY. Grand Rounds: “GVHD prevention by selective depletion of the alloreactive T cell repertoire.”

Mar 2008 Tallahassee Memorial Hospital, Grand Rounds, Tallahassee, FL. Lecture “Myelodysplastic Syndromes from Diagnosis to Treatment”

Mar 2009 MD Anderson, Houston, TX. Grand Rounds Lecture “Clinical Trials are Best”

Apr 2009 Baylor College, Houston, TX. Grand Rounds Lecture “Yin-Yan of T-regs in GVHD and GVL”

July 2010 Fred Hutchinson Cancer Research Center. Grand Rounds Lecture “GVHD 2020”

Oct 2012 Japanese Red Cross Nagoya, Dai-ichi Hospital, Nagoya, Japan. Meet the Professor, Nagoya, Japan. Lecture Title: “The secrets of preventing and managing GVHD”.

Oct. 2012 National Cancer Center Hospital, Tokyo, Japan. Lecture Title: “Prophylaxis and treatment of GVHD”.

##### **5. Special Seminars to Biotechnology and Pharmaceutical Companies:**

Nov 1992 Roche, Basel, Switzerland: Seminar on “Human GVHD”.

Dec 1992 Scientific Symposium of the Clinical Research Committee, Roche, Nutley, NJ: Lecture on “The role of the IL-2 receptor in human GVHD”

Mar 1993 Protein Design Labs, Mountain View, CA: Lecture on “The role of IL-2 receptor in human GVHD”.

Feb 1994 ICOS Corporation, Bothell, WA: Seminar on “The role of CD28 in T cell costimulation and anergy”.

Jul 1994 Humanized Anti-Tac Mini Symposium, Roche, Little Falls, NJ: Lecture on “Prevention of acute-graft-versus host disease”.

Oct 1994 DNAX, Palo Alto, CA: Lecture on “Tolerance to allogeneic stem cells in man”

Feb 1995 Roche Transplant Meeting, Basel, Switzerland: Lecture on “Unrelated bone marrow transplants”.

Mar 1998 Investigators’ Roundtable Discussion on Daclizumab, Miami, FL. Presentation: “The Use of

Sept 1998 Antibody Therapy in the Prophylaxis and Treatment of Graft-Versus-Host Disease.”  
Genetic Institute, Cambridge, MA. Lecture: “Is there a Role for CD28-targeted  
Immunosuppression to Prevent GVHD in Humans?”

Feb 1999 Humanized Anti-CD3 Antibody (HuM291) Advisory Board Meeting. San Francisco, CA.  
Presentation: “HuM291: Background and Mechanism of Action.”

Apr 1999 Nexell – Hi Risk Allogeneic Transplantation Advisory Meeting, Newport Beach, CA.  
Presentation: “Matched and Mismatched Unrelated Donor Allogeneic Stem Cell  
Transplantation; Outcomes and Strategies for the Prophylaxis and Treatment of GVHD.”

Feb 2001 Advisory Board Meeting on: IV Busulfan: Clinical and Pharmacokinetic Strategies with New  
Dosing Regimens. Attendee.

Sept 2001 Genencor International, Inc., Palo Alto, CA. Consultant.

June 2002 Sangstat, Hematology Advisory Board Meeting; San Francisco, CA. Attendee.

Mar 2003 Sangstat Hematology Clinical Advisory Meeting, Fremont, CA. Chair.

June 2004 Palfermin Stem Cell Transplantation Advisory Board, Chicago, IL. Lecture: “Challenges in  
allogeneic hematopoietic cell transplant: From Bench to Bedside.”

Oct 2004 ESP Pharma IV Busulfex Advisory Board, Chicago, IL. Attendee.

Dec 2004 Genzyme Advisory Board, San Diego, CA. Attendee.

Mar 2005 United Resource Networks 7th Annual Meeting: Evolving Science of Blood/Marrow  
Transplantation & Cancer Treatments, Miami, FL. Presentation: “Selection of Alternative Stem  
Cell Donors: HLA Mismatched Related or Matched Unrelated?”

Nov 2005 Advisory Board Meeting: Pfizer Vfend Bone Marrow Transplant. Miami, FL. Attendee.

Mar 2006 Cigna Lifesource Seminar, Pittsburgh, PA. Presentation: “MDS: The Achilles Heel or The Cure  
/ How/when does it present? How should it be managed?”

Sept 2013 Tobira GVHD Advisory Board. Chicago, IL. Attendee.